Investors, Strategics & Innovators

Bio coming soon.

Bio coming soon.

Scott will join his team of exclusive sponsors to host the Emerging Medtech Summit. Scott's mission at the meeting will be to connect the investors, innovators and strategics that are driving the future of medtech.

Scott is the President, CEO and Founder of Life Science Intelligence.  He has been in the medtech market intelligence business for over 20 years supporting venture funded startups, major strategics, and life science investors as they navigate the ever-changing medtech marketplace.  Prior to founding LSI, he held senior executive roles with renowned life science data providers including Medical Data International, Medtech Insight and Windhover Information.  He has held leadership roles as a strategic partner for Elsevier Business Intelligence, Health Research Intelligence, and Informa Business Intelligence.  Scott and his team at LSI have conducted numerous market research projects for top medical device manufacturers including Johnson & Johnson, Medtronic, Boston Scientific, Abbott, Becton Dickinson, Teleflex, Cardinal Health, GE Healthcare, and Stryker, among others.   

Chris is a prolific entrepreneur and venture capitalist who has pioneered some of the most innovative medical technologies brought to market in the last decades. As Founder and Executive Chairman of Miraki  Innovation, Chris forecasts imminent global health and medical challenges, uncovers technologies  at leading research institutions and assembles teams of industry experts to solve these global problems.  Chris not only offers investments guidance and critical research and industry connections, but also  helps guide each portfolio company along the fund's proven, proprietary process that reduces new  venture risk and enhances returns.

Companies developed by Chris have created considerable value. Investments, returns and valuations from seven companies founded, developed and/or brought to exit by Chris have benefited from more than $5.77 billion in returns realized to all investors through exits. A recent example is Auris Health which was recognized by CNBC as one of the 50 most disruptive companies in the world. The Auris transaction was proceeded by a number of ventures by Chris that set gold standard for motion preservation, regeneration of cartilage and soft tissue through the use of novel peptides and regenerative medicine. Throughout his 27-year career, Chris has represented more than 150 medical device companies in a variety of business transactions including licensing agreements, joint venture partnerships and M&A.

Scott Huennekens will deliver the Keynote "Medtech 3.0 & Creating Unicorns" on February 18th at LSI 2021 Emerging Medtech Summit.  In his presentation, Scott will share his vision for the future of medtech and explain why he believes now is a great time to build, not backpedal.  

Huennekens has more than 25 years of experience in the medical device industry, specializing in clinical advancement through innovative R&D and technology-based initiatives. He currently serves as Executive Chairman of the Board for Acutus Medical (IPO in 2020).  He has held a number of executive leadership roles within the healthcare industry, accelerating the next generation of digital surgery for Verb Surgical and leading Volcano Corporation, an image guided therapy device company, to its IPO in 2006. He holds an MBA from Harvard University and a BS in Business Administration from the University of Southern California. Huennekens currently sits on the boards of public companies Viewray and NuVasive.

Mr. LaViolette will participate on an investor panel at Emerging Medtech Summit and will attend to network with other investors, strategics and medtech thought leaders.

Paul built and ran medical device businesses for 29 years before joining SV Health Investors. Most recently he was Chief Operating Officer at Boston Scientific (BSC), an $8 billion medical device leader. During his 15 years at BSC, Paul served as Chief Operating Officer; Group President, Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International. During his tenure, the company grew revenue over 20 times. Paul integrated two dozen acquisitions and led extensive product development, manufacturing and worldwide commercial organizations. Previously, Paul held marketing and general management positions at CR Bard and various marketing roles at Kendall (Medtronic).

Bio coming soo.n

Bio coming soon.

Bio coming soon.

Bio coming soon.

Rik brings over 17 years of healthcare experience to River Cities, including deep private

and public healthcare company investment experience. Rik focuses primarily on medical

device and healthcare IT investments. He is actively engaged alongside management in the

financing, marketing, product development, operations and identification of bolt on

acquisitions.

Prior to RCC, Rik worked with venture backed companies in the strategy of group of Scient,

an eBusiness consulting firm. Before Scient he worked at Andersen Consulting (Accenture),

first in the healthcare services group and then at the Internet Center of Excellence where he

helped launch several venture-backed companies as well as worked on the team that

developed the online music platform for BestBuy.

Rik serves on the board of Bardy Diagnostics, was on the board at EndoChoice (IPO and

then sale to Boston Scientific) and was an observer at Veran Medical (sold to Olympus) and

Pioneer Surgical (sold to RTI Surgical).

Academic credentials

BE Mechanical Engineering, Vanderbilt University; MBA, Duke

Outside of RCC

Rik enjoys spending time with his wife and three daughters, going to North Carolina

beaches and tinkering on his track car. He is a Boston native but escaped the cold to live in

the Research Triangle Park in NC.

Rakesh Mehta is a Managing Director in the Healthcare Investment Banking group. He has 21 years of experience in financial advisory services, M&A, private and public equity and debt financings and venture capital investments. Prior to joining J.P. Morgan, Rak was at Piper Jaffray, DLJ and Baxter Healthcare. Rak received a BA from Syracuse University and an MBA from Duke University.

26 years of extensive global experience as a Medical Device Executive. Adept at General Management, Mergers & Acquisitions,and Corporate Strategy. Passionate about transforming businesses through growth and innovation, developing talent, optimizing resources, creating enterprise value for shareholders, developing new products and executing strategic initiatives to deliver top line growth and increase profitability. 

Ms. Carmel is will run a panel on Panel on Venture Capital Investing in Medtech at Emerging Medtech Summit.  

Lisa is Vice President of Strategy at Ximedica.  In this role, Lisa is focused on building sustainable growth for the company. She leverages her experience in global product commercialization to help forge long-term collaboration and productive client relationships, with a core focus on Ximedica’s critical, strategic partners.​

Lisa has 25+ years of international commercialization of healthcare and consumer products with companies in the US, Europe and China. As co-founder of a healthcare management consulting firm, Lisa led projects involving commercialization strategy, portfolio assessments and due diligence, with special emphasis on medtech innovation. Clients and employers have included Procter & Gamble, MedImmune, Agilent and Emergent Biosolutions. Lisa also gained valuable hands-on startup experience as a founding executive of a commercialized medical device startup.​ An active member of the medtech startup and investor community, Lisa is as an advisor to many startups and accelerators including CLSI’s FAST program, Medtech Innovator and UCSF Health Hub. She also serves on the board of the California Life Sciences Institute, the innovation arm of California Life Sciences Association, and as an advisor to the Cleveland Clinic Medtech Advisory Board, UCLA’s Technology Ventures Group Advisory Board and Red Crow Angel Investor platform.

Greg brings over 15 years of healthcare transaction experience to SV, including deep private and public healthcare company investment experience. He joined SV in 2002 as an Analyst and later transitioned to the role of Portfolio Manager with both portfolio and lead fundraising responsibilities. Greg was promoted to Partner in 2019 and focuses on medical device and healthcare services investments. He is actively engaged in the financing, strategy, operations and acquisitions of portfolio companies.

Prior to SV, Greg worked at Testa, Hurwitz & Thibeault, in the Business Practice, Emerging Technology and Private Equity groups, supporting both venture capital funds and venture backed companies in business formations and financings, mergers and acquisitions, and venture capital fundraising.

Academic credentials
BA, Honors, Colby College; MBA, Honors, Boston University (graduating Beta Gamma Sigma).

Outside of SV
Greg enjoys spending time with his wife and two daughters, and playing golf (they are learning to enjoy it too). He is a Boston native and a graduate of St. Sebastian’s School.

Dr. Cheung will attend Emerging Medtech Summit to scout for new investment opportunities and network with fellow investors, strategics and industry.

Tak joined NEA in 2018 as a Principal on the healthcare team. He focuses on medical device investments.

Prior to NEA, Tak was a Venture Partner at Merieux Development Venture Fund where he led all phases of investment for healthcare startups, including sourcing, diligence and investment approvals. Tak also co-founded Lexington Medical, a commercial-stage medical device startup in the gastrointestinal surgery space. Prior to Merieux and Lexington, Tak was VP of Business Development for the Global Surgical Division at Bausch & Lomb, and was responsible for all business development efforts in the ophthalmic surgical division. Tak has held various corporate and business development leadership roles at Edwards Lifesciences in the Heart Valve Therapy Division and Advanced Medical Optics (acquired by Johnson & Johnson).

Tak received a BS with Honors in Engineering and Applied Science from the California Institute of Technology, an MD from the University of California, Irvine, and an MBA from Harvard Business School.

Kwame Ulmer is a MedTech executive with nearly 20 years of government and private sector experience. He integrates his time working as an operating company executive, evaluating over 1,000 technologies at the FDA, advising early stage companies, and formal business education to help clients set a clear regulatory strategy and deliver on key milestones. Kwame is based in Southern California.

Dr. Debbie Lin is Executive Director at Boehringer Ingelheim Venture Fund in the US and leads the Fund’s North American efforts in Digital Healthcare. She joined Boehringer Ingelheim Pharmaceuticals in 2008.  Within Boehringer Ingelheim Pharma, she worked across various regions and divisions.  She has worked in Medical Affairs in the area of women’s health and later in Health Economics and Outcomes supporting all commercial product sales with large payers and providers accounts on the West Coast. She also led the US organization’s social entrepreneurship program in Boehringer Ingelheim’s Making More Health collaboration with Ashoka.

In 2013, she transitioned to Corporate Headquarters in Germany in Corporate Strategy and Development as Director of Corporate Development.  There she was responsible for BI’s global development strategy, leading BI’s global venture into stroke rehabilitation. She led multi-country teams to set up the company’s first stroke rehabilitation centers in Shanghai, China and in Lisbon, Portugal.

Prior to Boehringer Ingelheim, she worked as a Public Policy Consultant for Pacific Health Policy Group supporting Medicaid Policy implementation in various states such as Vermont and West Virginia during the Clinton Administration. Her doctorate is in Pharmacogenomics and Bioinformatics from UCSF, she also has a Masters in Engineering from Stanford University and a Masters in Public Policy from UCLA.

Amy Belt Raimundo joined Kaiser Permanente as a managing director in 2016. Amy brings over 20 years of experience in healthcare investing, start-up and corporate operations and hospital system consulting.

Amy has spent a dozen years in venture capital including Covidien Ventures and Advanced Technology Ventures (ATV). Immediately prior to joining KPV, Amy was the Chief Business Officer of digital health start-up Evidation Health. Amy has spent close to a decade in venture capital at Covidien Ventures and Advanced Technology Ventures (ATV). Prior to KP Ventures, she led investments in Medina Medical (acquired by Medtronic) and Nevro Corporation (NYSE: NVRO) among others. Earlier in her career, Amy held operating roles at Guidant Corporation and began her career as a management consultant for hospitals at APM/CSC Healthcare.

Amy is a Kauffman Venture Fellow as well as founder and president of MedtechWomen. She holds a BA in Economics from Yale University and an MBA from the University of California at Berkeley.

Ms. Burke will attend the Emerging Medtech Summit to scout for new investment opportunities and to network with fellow investors, strategics and innovators.  

Terri is a Venture Partner with Epidarex Capital, where she leads the MedTech investment strategy. She is also co-founder and CEO of Protaryx Medical. Previously, Terri was a member of the Senior Leadership Team at Edwards Lifesciences and held multiple Vice President positions in the heart valve business, including managing a cross-functional technical development program, leading Global Marketing, and overseeing Business Development for several strategic acquisitions and partnerships. Terri has prior experience in health economics and reimbursement as a consultant with Covance and inproduct marketing with Guidant Corporation.

Terri holds a Board Director role with Raydiant Oximetry, is an active member of MedtechWOMEN and is a founding member of the Duke University Women’s Impact Network Athletics Leadership Council. Terri also acts as an Advisor for the Ignite Fire Pitch Competition. Terri holds a B.S. in Biology from Duke University and an MBA from the University of Southern California.

Bio coming soon.

Bio coming soon.

Kyle joined MVM in 2017. Prior to joining, he was a consultant at Bain & Company, working mainly in the healthcare practice to support medical device and healthcare provider clients. During his undergraduate and graduate education, Kyle was a prolific researcher and writer, publishing a half-dozen peer-reviewed papers on topics ranging from homologous chromosome pairing genetics to orthopaedic surgery outcomes. Kyle completed MD studies at Harvard  Medical School and MBA studies at Harvard Business School. He also holds an AB in biochemistry from Bowdoin College.

Mr. Root is attending the Emerging Medtech Summit to network with fellow investors, strategics and to identify new investment opportunities.

As a physician, Jon Root evaluates investments in the medical field with a practitioner’s eye. A common investment criteria when evaluating business opportunities in the biotechnology or medical devices fields is: does this solution meet, or begin to address, an unmet clinical need? Jon goes beyond that: is the innovation easily usable?

“The greatest idea in the world will not be successful if it’s not practical to use,” says Jon.

Jon spent nine years in clinical practice before joining USVP in 1995 as a Ewing Marion Kauffman Fellow in venture capital. He became a general partner in 1997. Before USVP, Jon was on the faculty and clinical staff at The New York Hospital-Cornell Medical Center in New York City. There he was an Assistant Professor of Neurology and Director of the Neurology-Neurosurgery Special Care Unit. He is board certified in neurology.

“Efficacy always dictates the doctor’s choice of procedure or method,” Jon notes. “It’s critical to gain feedback from the people who will actually use your product,” he says. Whether it’s less invasive biopsy procedures or simple changes that make a tissue closing easier, considering the doctor as well as the patient helps optimize product design, Jon adds. “If an easier way is just as effective, there is opportunity for companies to make a difference. If a drug is as effective taken orally versus intravenously, the doctor will probably choose a pill — if it’s available.”

Jon is currently on the boards of USVP portfolio companies of Cleave Biosciences, eFFECTOR Therapeutics, HealthJoy, Inari Medical, Nuvaira, Okami Medical, Omada Health, Ribon Therapeutics, Route92 and Swoop. Jon is a former board member for the National Venture Capital Association (NVCA).

Jon maintains relationships with leading medical schools on both coasts and enjoys helping entrepreneurs make meaningful connections. He helps entrepreneurs connect with leading specialists to gain input on product design issues.

Jon holds an A.B. in Economics from Dartmouth College, an M.D. from the University of Florida College of Medicine, and an M.B.A. from Columbia University.

Jon enjoys golf, plus he likes to swim and ride bicycles with his wife and two sons.

Bio coming soon.

Bio coming soon.

Oliver joined Intuitive Ventures in 2019 and leads investment efforts with a focus on identifying future leaders of minimally invasive care, including early stage startups across digital, medical device, therapeutic, and diagnostic domains.

Prior to Intuitive Ventures, Oliver was a healthcare investor with GE Ventures, driving international-startup deal flow and supporting numerous portfolio companies operationally and at the board level. He also spent a number of years advising an array of UK, US, and global healthcare innovation projects across technology, government, commercial, and academic fields. He started his career as a junior doctor and policy advisor in the UK National Health Service and remains dedicated to bringing new technologies, diverse partnerships, and investment to address healthcare‘s biggest unmet needs.

Oliver holds an MD and BSc in pharmacology from the University of Edinburgh, Scotland. He is a widely published author in the fields of healthcare and surgical innovation, and is an advisory board member of the Newsom administration‘s California Initiative to Advance Precision Medicine.

Mr. McWilliams will attend the Emerging Medtech Summit to identify new investment opportunities for Sante Ventures, network with industry executives, and participate in the VC Investing in Medtech Panel.

Dennis has dedicated his career to bringing innovative life science ideas to the market. He is the Founder of SparkMed Advisors, a boutique advisory focusing on bringing creative solutions to medical device commercialization. Dennis previously was the Founder of Apollo Endosurgery [NASDAQ: APEN] and served as CEO for nine years from the company’s inception until 2014, where he assumed the role of President and Chief Commercial Officer. Prior to Apollo, he co-founded Chrysalis BioTechnology‚ a development stage biopharmaceutical company focused on developing novel drug therapies for tissue regeneration‚ including bone‚ cartilage‚ and dermal soft tissue. He started his career at the IC2 Institute, a think-tank based in Austin, Texas focused on applied research in entrepreneurship and commercialization. Dennis received a Bachelor of Science with honors from the University of Texas in Aerospace Engineering and a Master of Science in Engineering Management from Stanford University.

He has served on the Board for the Texas Exes and the University of Texas Men’s Athletics Council. In 2007, he was given the Outstanding Young Texas Ex Award by the University of Texas, in 2016 was named a Distinguished Engineering Graduate from the University, and in 2019 was named to the Academy of Distinguished Alumni for the Aerospace Engineering school. He is a frequent speaker and lecturer on entrepreneurship and innovation in medicine and serves as faculty for the B.E.S.T. Innovations Courses taught at the prestigious IHU Institut de Chirurgie Guidée Par L’Image in Strasbourg France, Taiwan, and Brazil.

Geoff Pardo joined Gilde Healthcare in 2011 as a Partner working out of the office in Boston/Cambridge, MA and is focusing on Gilde's investments in North America. He led the investments in Ablative Solutions, Inari Medical, Axonics Modulation Technologies (NASDAQ: AXNX), CVRx, InovaLabs (acquired by ResMed), BionX (acquired by Ottobock) and Vapotherm (NYSE: VAPO) and represents Gilde as a member of the board of directors for each company.

Previously, he was a Partner at Spray Venture Partners where he led investments into Interlace Medical (sold to Hologic), Solace Therapeutics, TearScience (sold to J&J) and Cascade Ophthalmics. He served on the board of Solace, TearScience and Cascade, and was actively involved in Interlace and Conventus Orthopedics.

Geoff also served as President & CEO of Facet Solutions, a spinal implant company focused on treating lumbar spinal stenosis until the company was sold to Globus Medical in 2011. He has also worked at Cardinal Partners as an Associate leading their investing activity in the medical device sector.

Geoff began his career in medical devices as a product manager with Synthes USA.

He has a B.A. with honors in History from Brown University and an M.B.A. from the Wharton School of Business. He is a US citizen based in Gilde Healthcare's Cambridge, MA office.

Paul oversees Arboretum’s investment process and leads the firm’s operations. His portfolio investments focus on capital-efficient health IT and service companies applying technology to underserved markets. Paul currently serves as a board director for BioIQ,  Adavium Medical,  and Delphinus Medical and is the former Chief Operating Officer for CerviLenz (now Lucina), where he led the design of the company’s first commercial product from concept to launch.

Prior to joining Arboretum, Paul worked at Ford Motor Company holding management positions within product development, manufacturing, and business strategy. He currently serves on the National Advisory Board for the Institute for Healthcare Policy & Innovation at the University of Michigan.

Paul earned a BS and MS in Mechanical Engineering from the University of Michigan and an MBA from the Ross School of Business at the University of Michigan.

Bio coming soon.

Sean is an investment professional at Philips Ventures, which manages a portfolio of early-stage investments in Digital Health aligned with the Philips HealthTech strategy. He was previously part of Philips Group Strategy advising the C-suite on topics including AI, digital transformation, IoT, data, and platforms in healthcare. Sean has held positions at The Boston Consulting Group, U.S. FDA, and NASA. He has a PhD from the University of Cambridge, where he developed fluid dynamics algorithms for medical device applications. He continues his engineering pursuits as an Adjunct Professor at Soochow University.

Outside of the office, Sean is focused on social impact and education, and currently drives several related initiatives around Boston (ask him). He also sits on the Advisory Councils of The Johns Hopkins University’s Department of Biomedical Engineering as well as the World Economic Forum's Global Shapers Community.

Sean Cheng was a Co-Founder at Solenica.

Bio coming soon.

Charles Warden is a Managing Director who has been a medical device venture investor since 1992. He works closely with entrepreneurial device companies every step of the way, from inception to success.

Greg is an executive with extensive experience in running medical technology companies, including managing and leading people at all levels, as well operational management and business strategy and planning.

Originally an attorney at Pillsbury Winthrop, Greg began his medical technology career at Guidant Corporation where he held a number of executive-level legal and business development positions in different Guidant operating companies. Following Guidant's acquisition by Boston Scientific, Greg joined Acclarent, Inc. where he served initially as Vice President of Corporate Development, and then as Acclarent's Chief Operating Officer through the acquisition and integration of Acclarent by Ethicon, Inc., a Johnson & Johnson company.

Bio coming soon.

Jeff Peters is a Venture Partner with OrbiMed. Mr. Peters has over 25 years of medical device experience and currently serves as the President and Chief Executive Officer of Cardialen. From 2014 to 2017, Mr. Peters had several financial and operating consulting roles in public and private companies.  Previously, Mr. Peters was the Chief Executive Officer of Anulex Technologies, a company developing minimally invasive spine therapies; he also served as the Chief Technology Officer of ev3 (now Medtronic) from 2001 2007.  Mr. Peters’ prior financial roles include Portfolio Manager at Black River Asset Management, Entrepreneur in Residence at Foundation Medical, and Stock Analyst at Dain Rauscher Wessels. Mr. Peters received his B.S. and M.B.A. from the University of Minnesota.

Daniel is a career CFO/COO who has directly led 29 investments, totaling more than $500 million. He has also orchestrated divestments of a similar scale and arranged hundreds of millions of dollars of debt financing for various companies in the US, Asia, South America, and the Middle-East. He was an early innovator in several private asset-backed investment trusts between 2007 and 2011, and the driver behind the establishment of a small $10M in-house venture fund for a Fortune Global 50 company. He has consulted for a number of Silicon Valley venture funds that are focused on commercializing leading-edge US technologies in China.

Daniel has been a CFO for both private and publicly-listed companies, start-ups as well as Divisional CFO for Fortune 500 companies. He has been involved in the medical devices space since 2007 and was most recently, the CFO of Reach Surgical, where he was also responsible for the international business and all its international joint ventures.

He has a Bachelor’s degree in Natural Sciences with an emphasis on medical physics from Cambridge University, a Master’s degree from the Stanford Graduate School of Business, as well as, finance and accounting qualifications from the ACCA in London. While at Cambridge and at Stanford, he was respectively, a Cambridge Commonwealth Fellow and an Alfred P. Sloan Fellow.

Mr. Ryan will attend the Emerging Medtech Summit to identify investment opportunities for Wells Fargo Strategic Capital.  He'll also particpate in a panel to share his perspective on market trends and opportunities.

John has been a private equity investor in the healthcare industry for more than 20 years and has participated in the founding, building, and financing of companies, ranging from early startups to established industry leaders, across health care sectors including medical technology.  John is currently a Managing Director with the Healthcare Division of Wells Fargo Strategic Capital (WFSC), which provides venture and growth private equity and debt capital financing solutions to companies across most sectors of the healthcare industry.  Earlier in his career John was a Managing Director with ONSET Ventures and before that he focused on health care related investments for JPMorgan Partners and Morgan Stanley Venture Partners.  Prior to his work as a venture capital and private equity investor, John worked with Morgan Stanley as an investment banker serving healthcare companies.  John holds an M.B.A. from the Harvard Business School and a Bachelor of Science degree with high honors from the University of Colorado.

Former Partner at Sofinnova Partners

Invested followed and exited over 10 Start-ups & SMEs in Europe

Deep knowledge of technology development acquired through several roles at leading Electronics companies and Labs (STM, LETI)

Msc in Chemical Engineering @ Politecnico di Milano and MBA ESCP-EAP, Kauffman Fellow

Bio coming soon.

Johnson & Johnson (J&J) is the world's largest healthcare company, and its group of Innovation Centers is a unique vehicle to accelerate early innovation and enhance opportunities for collaboration and investment across J&J's healthcare businesses. Nick’s role within the New Ventures group at the CA Innovation Center (IC) focuses on medical device innovation in support of the general surgery, orthopedics, and cardiology businesses. His charge is to identify licensing, collaboration, and investment opportunities highly aligned with J&J business strategies by building relationships with entrepreneurs, venture investors, and key opinion leaders. The New Ventures team employs a broad array of deal structures in order to best fit the specific needs of the innovation opportunity, often in collaboration with JJDC [equity investments] and JLABS [incubator]. Website: http://www.jnjinnovation.com

Bio coming soon. 

Barbara Lubash is a Managing Director specializing in healthcare services and information technology at Versant. In her career as an operating executive and venture capital investor, Barbara has led and advised provider, payer and healthcare IT organizations throughout the U.S.

Prior to co-founding Versant Ventures, she was a Partner at CrossPoint Venture Partners. Barbara formerly was a division President at PacifiCare Health Systems, and was Senior VP at PHCS, a national PPO. Her operating career also includes management roles at the hospital information systems division of Hewlett Packard and the Harvard Community Health Plan, where she managed one of the first U.S. electronic medical records installations.

Mr. Pachuda will attend the Emerging Medtech Summit to identify new investment opportunties and he'll also participate in a panel discussion to share his view of trends in our industry.

Nick is the leader and Worldwide Vice President of Orthopedic Innovation for the J&J Medical Device Group.  He is responsible for making J&J the partner of choice for Orthopedic Innovators around the world.  He works to find the best external sources of science, technology and talent to bring transformational and clinically translatable orthopedic solutions to patients. He has worked in all segments of Orthopedics including sports, extremities, trauma, joints, spine, digital surgery and tissue regeneration.

Nick was in clinical practice for 10 years specializing in Foot & Ankle Surgery after completing his fellowship in Orthopedic Trauma. 

Benjamin Glenn is a partner at Shay Glenn LLP, where he specializes in strategic patents and innovations counseling. Benjamin’s litigation, patent prosecution and strategic counseling experience in a range of technologies allow him to assist clients in establishing and protecting valuable intellectual property portfolios. Benjamin primarily advises venture-backed companies and investors in intellectual property matters arising during investment rounds, corporate formation, and throughout a company’s product development cycle with an emphasis in companies within the medical device industry.

Benjamin graduated from the United States Naval Academy in 1987, receiving a B.S.E. in mechanical engineering. He served in the United States Navy until 1995 in a variety of engineering positions relating to power generation and distribution systems, propulsion systems, and water purification systems. While attending law school at Santa Clara University, Benjamin operated his own patent agent practice, providing patent and counseling services to established and emerging technology clients. Prior to opening the Shay Glenn LLP, Benjamin was a division patent counsel with Applied Materials, Inc. and was associated with Wilson Sonsini Goodrich & Rosati, and Cooley Godward LLP in the areas of intellectual property litigation, patent prosecution and innovation counseling.

Benjamin is admitted to practice in California and is registered to practice before the U.S. Patent and Trademark Office.

Kevin joined MVM in 2016. Prior to MVM, he worked across the life science and healthcare sector as a consultant at Bain & Company. Kevin completed his PhD in Oncology at the University of Cambridge, where he conducted translational research in the field of neural development.

Kevin is a member of the board of Zipline Medical, Inc.

Luba brings to Google pharmaceutical, biotechnology, and digital health industry experience and expertise in building and investing in innovative technology companies and providing strategic counsel to global corporations. Previously, Luba has served as Vice President of Global Business Development and Mergers & Acquisitions at Roche, where she also established and led the East Coast Innovation Hub for the Diagnostics Division. Luba is on the Board of MassBio and Brooklyn ImmunoTherapeutics, and serves as Advisor to the Dana-Farber Cancer Institute, as part of its Business Development Council. Luba is a Thought Leader for the New England Journal of Medicine (NEJM) Catalyst, Founder of the Pharma Digital Health Roundtable, and a Lecturer at Boston University Law School and School of Management where she has taught courses in life sciences, business law, innovation, and entrepreneurship since 2014.

Luba’s career has spanned leadership roles in venture investing, business development, Mergers & Acquisitions, law, and operations, previously serving as Venture Partner at Colt Ventures, leading BD and Strategy for Axcella Health, a Flagship Ventures company, and serving as Senior Mergers & Acquisitions Counsel at Pfizer Inc. Luba began her career practicing law at a leading national law firm, Wilmer Cutler Pickering Hale and Dorr, where she represented clients in securities, IP, regulatory, corporate, and litigation matters.

Luba is a recipient of several awards and honors for her work in the community, including the Science Club for Girls Catalyst Award for her commitment to advocating for women in science and technology. Luba served as a non-profit board member of Longwood Symphony Orchestra, executive coach for MassNextGen, co-chair of MassBio’s Entrepreneur’s University, and mentor and judge for MassCONNECT, MIT 100K Entrepreneurship Competition, and MassChallenge.

Mr. Krantz will participate on the panel "Future Trends in Medtech Innovation: 2020 Vision" and will attend Emerging Medtech Summit to scout for new opportunities and network with other strategics, investors and innovators.

Bio coming soon.

Mr. O'Neill is an active early stage medtech investor and is Managing Director of Venture Capital Investments for Connecticut Innovations.

Rob will share his medical device investment interests at the Emerging Medtech Summit.  Rob is CEO of Shoulder Innovations, Genesis Innovation and the Cultivate(MD) Fund where he focuses almost exclusively on early-stage medical device investments.

Rob has spent more than two decades bringing medical device technologies to market, including proprietary orthopedic materials.

Rob served at Tornier as Global Vice President, Research and Development, during which time Tornier grew from approximately $70M to $300M in annual revenues through organic growth of new products.  He holds more than 30 issued or pending patents.

BD, commercialization and marketing executive with 10+ years of operating experience in medical device industry and proven track record of organizational growth management and strategic market development in Greater China and South Korea. Educational background includes MBA from Harvard and Biomechanical Engineering degrees from Stanford. Bilingual leader well-versed in corporate cultures in the healthcare industries of both Greater China and the United States. 

Bio coming soon.

Michael Thomas has over 23 years of experience in the healthcare industry in various executive leadership positions. Currently, he is the President and CEO of Appian Partners, healthcare advisors focused on strategy development and implementation for medical device and healthcare services firms ranging in size from early stage startup to Fortune 50 global conglomerates. Additionally, he is CEO of Regear Life Sciences LLC, where he is working to re-invent deep heat pain management with a direct-to-consumer, wearable diathermy device.

Previously, Mr. Thomas was CEO of iSonea Limited, a Melbourne, Australia based, publicly traded (ASX:ISN) respiratory medical device firm focusing on technology and smartphone app development for home asthma monitoring. Within eighteen months, the company’s market capitalization increased 6,200% from $4MM to $245MM. He raised $25MM from new and existing investors; drafted and implemented a new, long-term mobile health strategy; reduced monthly cash burn by 40%; reduced headcount from approximately 40 FTEs to 12; and hired a new executive team with extensive medical device development and launch experience. Mr. Thomas led iSonea to launch the world’s first asthma mHealth monitoring tool and smartphone app in Australia and secured FDA 510k OTC clearance for the asthma medical device to monitor wheezing.

Formerly, he was President and CEO of Sleep Solutions Inc. (now NovaSom Inc.), a venture capital-backed medical device manufacturer and national healthcare service provider. He raised over $50MM in venture capital funding to develop and launch a new industry in the $5 billion Sleep Medicine market. He successfully lobbied the largest Managed Care Organizations (MCOs) and the Centers for Medicare and Medicaid Services (CMS) to alter their medical policy and approve reimbursement for in-home sleep apnea diagnostic testing services.

Mr. Thomas was also a member of the Board of Directors for AdvaMed, the world’s largest and most prestigious medical device association. While a BOD member for AdvaMed, he participated in the successful renegotiation with the FDA for the MEDUFMA II legislation (the FDA’s regulatory approval process for medical devices), with leaders on Capitol Hill regarding the Remote Monitoring legislation, and sat on the BOD sub-committee for International Affairs.

Earlier he was Executive Vice President of Sales and Marketing for National Sleep Technologies Inc. (NST). As an executive and Board member, he identified and closed 12 acquisitions representing over 80 sleep labs, which led to NST becoming the largest U.S. sleep-testing company at that time. He helped create the first national brand in the highly fragmented sleep apnea diagnostic lab testing market. He recruited and managed a sales and marketing team that achieved a sales growth rate that was 2 times greater than the industry average for four consecutive years, and helped to raise over $15MM in venture capital financing.

As the Vice President of Sales for Patient InfoSystems, Inc., (NASDAQ: PATI) a healthcare IT start-up developing disease management programs, he was instrumental in taking the company public within two years. Previously, he held various sales and marketing positions, including seven years with Merck and Glaxo Wellcome, and has earned numerous awards for sales and management achievements. Mr. Thomas graduated from Cornell University with a bachelor’s degree in Microbiology.

Ms. Gaddy is Managing Director at BioPacific Investors, an angel group that invests in early stage medtech companies.  Ann will be attending the Emerging Medtech Summit to get business updates on exisiting portfolio companies and to identify new investment candidates.

Bio coming soon.

Mr. Akhavan is attending the Emerging Medtech Summit to identify new investments.

Omid is currently a Managing Director at Anthro Ventures, investing across medical devices, diagnostics, digital health and healthcare services. Previously, he worked as an Investment Principal at MVM Life Science Partners LLP and Becton Dickinson as Director of Strategy and Business Development. Prior to that, Omid was a management consultant at Monitor Deloitte in the Life Sciences and Healthcare team. Omid holds a Masters in Bioengineering from the Johns Hopkins University and a Bachelors in Biomedical Engineering from the University of Virginia. He also received a Fulbright Award to conduct research on access to healthcare in the Middle East.

Mr. Sym-Smith is attending the Emerging Medtech Summit to identify new investment opportunities and scout the future of medtech.

David Sym-Smith, is a Partner at Mobility Ventures who is a 25 year mobile industry veteran with a solid record of building multi-million dollar operations from scratch along with profitable exits.  Most recently, David served as Interim CEO at IndoTraq, the developer the fastest and most precise wireless indoor 3-D tracking system.

David has served as senior executive of global corporations as well as at multiple startups. He has a proven record of success in launching new markets, turnarounds, starting new business groups, building sales channels, introducing new products and services, winning market share and exceeding revenue and sales goals. 

Prior to joining Mobility Ventures, David served as the Chief Strategy and Marketing Officer of Tele Atlas. David managed global marketing, strategic planning, and product development for this leading global provider of digital maps and location content. Company doubled in size and was sold to TomTom for over $3 Billion.  Previously David served as the SVP of Global Business Development and Marketing at InnoPath, where he managed global marketing, product development and business development for InnoPath the industry leader in over-the-air (OTA) software updates and mobile device management (MDM) solutions. He Increased market share to 70% and revenue by more than 100%. David also helped launch Command Audio Corporation as Senior Vice President of Global Sales and Marketing, successfully leading the company from beta to launch to spin-off,  growing the company from 20 to over 100 people with over $80M in funding from Tier 1 VC’s and strategic investors (partially acquired by iBiquity).

David was a member of the founding core management team of Aerial Communications, serving as Regional President; he helped grow the organization from a mobile telecom start-up from early pre-launch phase, to a large entity with a $1.1B market cap within one year and was sold thereafter for more than $3.0B to T-Mobile (VoiceStream). At Sprint Spectrum he led Marketing and Product Development in launching the first PCS network in the country and first GSM network in the Americas.  Helping build a startup into an 800-employee, $150M revenue business in only the second year of service, and exiting with Sprint PCS’s purchase of operating control

David has also held senior management positions at CellularOne, AT&T, GTE, Saint-Gobain (France) and The Hay Group. He holds an M.B.A. from Pennsylvania State University – Smeal College of Business.

Ken's extensive experience in the cardiac monitoring and cardiac rhythm management market includes most recently leading the sales and strategic partnership activities as the US Vice President of Sales and Director of Business Development for BioTelemetry (formerly CardioNet), where he helped transform declining sales to 19 consecutive quarters of revenue and share growth, drastically reduced sales team turnover, and led several high-value strategic partnerships and acquisitions in the cardiac monitoring space. Previously, Ken was national Vice President of Sales and Marketing for iRhythm Technologies, where he built the entire foundational sales and marketing team for the US and substantially grew product sales ten-fold. In addition, he also served at Boston Scientific (formerly Guidant) in their Cardiac Rhythm Management Division for 8 years in various sales leadership roles. Ken earned a B.A. in Economics from Vanderbilt University.

David will attend the Emerging Medtech Summit to represent Alira Health's extensive advisory services and to network and meet with other industry insiders.  He will moderate the panel "Big Company Executives Turned Entrepreneurs."

David joined Alira Health with over 25 years of management experience in the medical device, products and clinical diagnostics field. He has lead strategy development, strategic planning and business development activities in these fields for mid and large cap public companies. David has directed business development deals ranging from M&A, licensing, distribution and co-development for companies such as Medtronic (legacy Covidien) in their respiratory and medical products business, as well as Hologic and Boston Scientific. He has held management roles at Integra Lifesciences and Abbott Labs. David has a BA from Clark University, Worcester, MA and an MBA from Thunderbird, School of Global Management, Glendale, AZ.

David Uffer joined Alira Health with over 25 years of management experience in the medical device, products and clinical diagnostics field. He has lead strategy development, strategic planning and business development activities in these fields for mid and large cap public companies. David has directed business development deals ranging from M&A, licensing, distribution and co-development for companies such as Medtronic (legacy Covidien) in their respiratory and medical products business, as well as Hologic and Boston Scientific. He has held management roles at Integra Lifesciences and Abbott Labs. David has a BA from Clark University, Worcester, MA and an MBA from Thunderbird, School of Global Management, Glendale, AZ.

Mr. Lateef will moderate the investor panel "Non-Traditional VC, Family Office, Angel & CrowdSourcing in 2020" at Emerging Medtech Summit and will represent Knobbe Martens to network with industry executives.

Irfan brings a wide range of experiences to helping clients achieve their goals. He works tirelessly to provide the right result in litigation, negotiation, risk management, tactical brand development, technology-focused initiatives and strategic IP mobilization. Being personally committed to the clients he serves is Irfan’s personality – and he keeps fighting to the end to ensure they are satisfied.

With a focus on patent litigation and dispute resolution, Irfan provides strategic vision from his extensive courtroom, patent portfolio development, regulatory, and business experience across many industry sectors. When defending his clients’ interests across the U.S. and abroad, Irfan has obtained significant awards for plaintiffs and consistently succeeded at all levels of litigation, including early settlement, motions for summary judgment, jury verdicts, and on appeal. Notably, Irfan represented and navigated medical device maker Masimo to a complete victory and jury verdict of over $466 million against Philips for infringing two Masimo patents. The jury also rejected Philips’s infringement claims seeking $169 million.

With nearly two decades of experience, Irfan has assisted clients in a wide range of technically complex industries to develop robust and valuable portfolios. Because of his extensive industry knowledge, whether electronics, medical devices, augmented reality, or AI, he is able to rapidly learn new areas of technology and quickly apply this knowledge to developing meaningful protection. Irfan’s practical business experience has ranged from initial product design, to IP rights tactics and monetization objectives, to ongoing development and market penetration initiatives. He is well-versed in the challenges his clients face and the questions that must be addressed and answered when it comes to problem-solving and to providing legal solutions that actually fit their business and financial objectives.

Passionate about his clients, their innovation and distinctive goals, Irfan is careful, considerate and helpful by nature, and strives to provide value far beyond legal counsel by focusing on the development of productive relationships across his practice. Ranked among the premier IP litigators in Super Lawyers magazine and in the "World's Leading Patent Professionals" for the Patent 1000 guide by Intellectual Asset Management (IAM) magazine, Irfan has also been listed in the “Legal 500.” Moreover, he is included among the Daily Journal’s “100 leading IP attorneys in California” for his extraordinary representation of Toshiba Corp.

Bio coming soon.

Bio coming soon.

Ms. Shusa will attend Emerging Medtech Summit to scout for new technologies, alliances and strategic partnering opportunities.

Mr. Merrill will attend the Emerging Medtech Summit to identify investment opportunities in early stage medtech ventures.

Jeremy works in Business Strategy at Tribeca Companies.  With more than 20 years of strategic and marketing medical device experience focusing upon early stage MedTech.  Jeremy has worked for companies with combined exits of over $8 billion.  Prior to joining Tribeca Companies, he was Head of Clinical Development at Mainstay Medical, a pioneering neuromodulation company.  He has also worked at Advanced Bionics Corp., Boston Scientific, MiniMed Inc., Bioness Inc., and Alfred Mann Foundation, among others.  

Jeremy holds a bachelor’s degree from Middlebury College, a Master’s of Public Affairs from Indiana University, and an MBA from UCLA. He is an active classically trained musician, supporter of the arts, and is a former board member of the Guitar Center Music Foundation and Fender Music Foundation.

Vice President of Clinical Development

Senior level manager with experience in B2B strategy, business development, sales and marketing in a highly competitive medical marketplace. Leading teams in the development of strategic plans, growing and diversifying customer base and industry segments, managing sales growth for North America, driving profitability and EBITDA targets, assisting in developing and managing cross functional & international teams, marketing/branding activities, communicating value proposition at all levels and maximizing shareholder value.

Specialties: Strategy, business development, solutions selling, marketing, branding, positioning strategies, orthopedic and medical device industry, medical industry network. 

Joining KPV in 2019, Tiffany brings over 7 years of experience working with stakeholders across the healthcare spectrum, including pharma, medtech, provider, and payer. She has conducted research on genomics in precision medicine and synthetic biology, and is particularly interested in the use of AI and technology to improve patient care.

Tiffany began her career as a Senior Life Sciences Consultant at L.E.K. Consulting, where she helped life sciences and healthcare clients tackle major strategic decisions including R&D/pipeline optimization, M&A, pricing strategies, and international expansion. During this period, Tiffany also spent time working in London and was on externship to Amgen working on Customer Experience and Innovation. Before joining KPV, she also obtained venture capital experience at GE Ventures and Bessemer Venture Partners in the healthcare and life sciences sectors.

Tiffany holds a B.A. in Business and Economics from UCLA, with a minor in Film and Television Criticism, and an MBA from Harvard Business School.

Edward Hanlon joined Gilde Healthcare in 2020 in the Cambridge office and focuses on Healthtech.

Prior to joining Gilde, Edward worked in advisory for Health Advances, a consulting firm operating across healthcare sectors in medical devices, biopharma, health technology, and diagnostics. He has broad experience in commercial strategy and M&A due diligence, advising a range of clients including late-stage start-ups, multinational corporations, and financial investors.

He has a B.S. in biology from Duke University. During his undergraduate years, he worked as a research assistant at the Duke University Center for Cognitive Neuroscience and the Liberty Mutual Research Institute Center for Behavioral Sciences. Edward is a US citizen.

Dan Secor joined Gilde Healthcare in 2020 in the Cambridge office and focuses on the Healthtech sector.

Before joining Gilde, Dan worked as a consultant at Health Advances, assisting clients across all sectors of healthcare in commercial strategy and M&A due diligence. Project work included go-to-market strategy and launch planning, indication prioritization, competitive analysis, and forecasting.

Dan studied physics and economics at the University of Pennsylvania. Dan is a US citizen.

In this role, he provides deal leadership in partnering with early stage companies across the medical device sectors.

Peter has been with J&J since a business school internship in 1990.  He joined the JJIC in November 2016.  His previous position was Vice President of Strategy for DePuy Synthes Orthopedics and Business Development for Codman Neuro.   Prior to that, Peter held a series of VP positions in Marketing, Strategic Marketing and Business Development for Mitek Sports Medicine and Codman Neuro.  He helped reposition Mitek from purely shoulder anchors to arthroscopy enabling solutions and to earlier intervention, exemplified by Orthovisc and Monovisc HA injections for OA.  At Codman Neuro, he helped redefine their business by divesting the Instruments business unit and emphasizing neurovascular stroke intervention, exemplified by Micrus,  Pulsar and Neuravi.

Before his stints in Ortho and Neuro, Peter spent the first half of his career in the Ethicon Surgery businesses, starting in Operations before going into Field Sales and into Marketing, including working in Scotland as Director of European Marketing for Ethicon.

Peter studied Chemical Engineering at Princeton on an ROTC scholarship before serving with US Army Forces in West Germany and attending Harvard Business School. He is on the Board of Directors of MassMEDIC and the Harvard Business School Healthcare Alumni Association.

Richard is the former CEO at Reach Surgical, a surgical instruments company, where he spent 15 years growing the company into an industry-leading, international brand with presence on six continents. His tenure there culminated in the recent sale of the company to private equity. During his time at Reach Surgical, he was the architect in a series of investments in the US, South America, China and Korea. These investments totaled more than $40 million and doubled the company’s revenues over three years. He also managed the construction and transition to a new 215,000 sq ft manufacturing facility. 

Prior to Reach Surgical, he led a variety of R&D projects at J&J in the US. Richard holds a degree in Electrical Engineering, has an MBA from the University of Cincinnati as well as a Ph.D. in Medical Imaging from Purdue University. 

He is now the Founding Partner and Managing director of Hunniwell Lake Ventures, where he is using his experience to launch a new fund that will invest in overlooked segments of the medical device space.

Allan brings over 30 years of early stage medical device investing to the Medtech Convergence Fund (MCF) and he is also Co-Founder of Life Science Angels.

The Medtech Convergence Fund is a $90M (2020) fund focused on early stage medtech deals.

Life Science Angels is a Bay Area early stage investment group focused on supporting innovative biotech, medical device, diagnostic and mobile health companies. Allan was also co-founder of Emergent Medical Partners, a $70M venture fund focused on early-stage medical device and diagnostic companies. Allan has been Chairman or CEO to 10 start-up medical device and diagnostic companies, and an investor in over 65 medtech, biotech, and diagnostic start-ups since 1995. In addition, Allan co-founded Nanostim, developer of the first Leadless Cardiac Pacemaker, and Hyalex Surgical, developer of synthetic cartilage for total joints.

Tico Blumenthal is the Chair of Life Science Angels, a Silicon Valley based angel group focus with a keen interest in medtech investments.  Tico is also the Director of Global Strategic Marketing for Cordis.

Adam is a seasoned entrepreneur with nearly 10 years of experience in enterprise SaaS. He has founded tech companies that have served over 10-million users and generated millions in revenue. Adam graduated from Hampden-Sydney College with a BS in economics.

Coming soon.

Jack joined MVM in 2019. Prior to MVM, he was a consultant at Bain & Company, where he served global pharmaceutical clients and medtech clients and specialized in due diligence for private equity firms looking at potential assets in the healthcare and life science sectors.

Prior to consulting, Jack practiced medicine in the UK. He completed his MBBS at King’s College London and holds a masters in Mathematics from the University of Oxford.

Howard Leonhardt is an inventor and serial entrepreneur.  He has 21 U.S. patents for products for treating cardiovascular disease.  His TALENT stent graft developed in the early 1990′s holds a leading world market share for repairing aortic aneurysms without surgery.  His inventions have treated over 200,000 patients in 60 countries.

Alexandra MacLean joined TVM as a Principal in 2020. She has a broad background in business development investments in multiple therapeutic areas in the pharmaceutical and medical device industries. Most recently she was the Head of Licensing and Business Development at Imbrium Therapeutics. Prior to this experience, Alix held roles in the medical device industry with Plasma Surgical and Covidien. At Covidien, she worked on multiple M&A deals and venture investments to diversify the business. She began her career in the pharmaceutical industry at Merck & Co. in cardiovascular clinical development.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Mr. Julian’s role involves supporting investment decisions, portfolio company management and investment outcomes. He evaluates potential new portfolio company targets with emphasis on bottom-up valuation analysis and deal structure. In addition to these responsibilities, Mr. Julian is a member of the Firm’s research team and is regularly evaluating thematic industry opportunities.

Prior to joining the firm, Mr. Julian was an analyst at the hedge fund Round Table Investment Management, LLC where he was the youngest member of the firm’s investment committee. His duties included security analysis, industry assessments and derivatives trading. Prior to joining Round Table, Mr. Julian participated on the Men’s Varsity baseball team at Brown University.

Coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio comming soon.

Steven Tolle has just joined HLM Venture Partners. He brings to HLM 30 years of commercial healthcare technology expertise in the areas of strategy, business development, and product management. Steve has spent his career helping to develop and manage some of the most important themes in healthcare innovation and investment today, including artificial intelligence, diagnostic imaging/medical devices, electronic health records, population health, managed care and value-based pharmaceutical pricing.

Bio coming soon.

Pramod is passionate about connecting people and helping technical founders leverage technology to solve customers' biggest pain points. At 11.2 Capital, Pramod focuses on enterprise software, including SaaS, cybersecurity, developer tools & enterprise IT. Prior to 11.2 Capital, Pramod was Director, Strategy and Corporate Ventures at VMware, where he invested in 15+ companies including JFrog, CloudEndure, VeloCloud, Wavefront, CounterTack, HyTrust. Prior to VMware, Pramod held product management and operating roles at early stage startups Montalvo Systems and Ikoa, where he architected, built and shipped several generations of enterprise products. Pramod started his career as a staff engineer building Sun Microsystems’ flagship server UltraSparc. Pramod graduated from IIT Bombay with a major in Electrical Engineering. He has a Masters in Science from Purdue University and an MBA from the Wharton School of the University of Pennsylvania.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Dean is a member of the Green D Ventures investment team, bringing along investing and clinical experience in healthcare and startups. Most recently, Dean worked at Touchdown Ventures, where he helped lead a venture capital fund with a health system. Prior to Touchdown, Dean served as an active duty flight surgeon in the United States Navy, deploying to Japan and El Salvador as the sole medical provider to over 300 Naval aviation personnel. Dean began his career in healthcare investment banking at Banc of America Securities and healthcare venture capital at KBL Healthcare Ventures. Dean has an AB in Government from Dartmouth (salutatorian Class of 2006), an MBA in Health Care Management from The Wharton School of the University of Pennsylvania, and an MD from the University of Colorado School of Medicine. Dean continues to serve as a flight surgeon in the Navy Reserve.

Frederik has over eight years of experience in investment banking and portfolio management (both equity and debt). Prior to co-founding 415 CAPITAL, Frederik led new business development efforts at Regis Medical GmbH, where he sourced and evaluated new MedTech investment opportunities, leading the due diligence process for several early-stage MedTech deals. Prior to joining Regis Medical in 2016, Frederik worked in HSBC’s Leveraged & Acquisition Finance group in New York City where he structured leveraged loans and high-yield bonds for private equity-backed buyouts and corporate M&A transactions including several mid- and large-cap Healthcare deals. Previously, he was in charge of the day-to-day monitoring of HSBC’s US private equity-backed credit portfolio. Before moving to New York City, he was an Analyst at HSBC in London where he advised clients on cross-border M&A transactions and IPOs. Frederik holds an Hon. B.A. in Economics magna cum laude from the University of Toronto (University College), Canada.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Jake brings a unique set of relationships and a financial research perspective to help NHVP’s clients raise capital. As a sell-side equity research analyst covering healthcare and technology companies at Credit Suisse, Imperial Capital and other Wall Street firms, he published detailed industry and company-specific analyses and worked closely with institutional investors. Prior to NHVP, he was a managing director at Rockport Venture Partners, where he specialized in healthcare and focused on digital health.

Jake holds an MBA from the NYU Stern School of Business and a BS in Management from Boston College. His West Coast sojourn at Yahoo! Finance years ago included introductions to yoga and surfing, which maintain a healthy place in his weekend warrior routine of playing and coaching local sports.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming.

Joshua Phillips is a Managing Partner of Catalyst Health Ventures and has led investments in med-tech, molecular diagnostic and life science companies.  He is currently a Director of Brixton BioSciences, Conformal Medical, Cruzar Medsystems, Saphena Medical, and Sera Prognostics.  Past investments include Novazyme Pharmaceuticals, Inc. (acquired by Genzyme Corp. NYSE:SNY), BioTrove, Inc. (acquired by Life Technologies Corp. NASDAQ:LIFE), Biocius Life Sciences, Inc. (acquired by Agilent Technologies, Inc. NYSE:A), Vortex Medical, Inc. (acquired by Angiodynamics, NASDAQ: ANGO), Allegro Diagnostics, Inc. (acquired by Veracyte, NASDAQ: VCT), SevenOaks Biosciences (Acquired by Medline Industries).

Prior to joining Catalyst, Josh was a Manager at the Lucas Group, a boutique strategy-consulting firm, where he led engagements advising healthcare, life science, and technology-based companies. In 1990, Josh co-founded, managed and built a new business unit at Russelectric Inc., a privately held engineering technology firm. In five years, the business achieved annual sales in excess of $5 million and employed 15 engineers and technicians. Josh previously held project and engineering management positions at Pratt & Whitney Aircraft focused on the integration of hardware and software for the control system of the USAF F-22 fighter engine.

Josh received a B.E. in Electrical Engineering and Mathematics from Vanderbilt University and an M.B.A. from the Harvard Business School.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Sean Freeman serves as senior vice president, strategy and corporate development. In this capacity, he oversees global corporate and geographic strategy, leads inorganic and venture initiatives, and manages the integration function.

Prior to joining NuVasive, Mr. Freeman held the same role at the Cole-Parmer Instrument Company and led corporate development at Life Technologies, a global life sciences tools company acquired by ThermoFisher in 2015. Prior to Life Technologies, he was an investment banker in the M&A group at Merrill Lynch & Co. in New York. Mr. Freeman is a CFA charterholder, holds a bachelor’s degree in commerce from the University of the Witwatersrand, and earned a master’s degree in business administration from The Wharton School at the University of Pennsylvania.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Jim Walker is President and Co-founder of Access Strategy Partners Inc, a key accounts management firm providing proven commercialization capabilities for leading-edge MedTech companies. A visionary leader and healthcare executive, Jim has more than 30 years of global professional experience in Sales, Marketing, Sales Operations and National Accounts management with Boston Scientific and Johnson & Johnson. 

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Renee Ryan has 25 years of building category-creating healthcare companies. She led the medical technology investments for Johnson & Johnson Innovation (JJDC) on the West Coast and Asia Pacific for 8 years. While at J&J, she made over 15 new investments, including the Series A for Cala Health. Previously, she was a healthcare investment banker at RW Baird, Jefferies and Goldman Sachs.

At the Emerging Medtech Summit Dr. Villafaña will share the story of Medical 21 (his latest venture) and discuss fundraising goals and strategic partner interests.

Co-inventor of the first lithium powered pacemaker and founder of Cardiac Pacemakers, Inc./Guidant.  All pacemakers now incorporate this technology.

Co-developer of the St. Jude heart valve and founder of St. Jude Medical, Inc.  This is the most commonly used prosthesis in the world.

Co-inventor of the ATS heart valve and founder of ATS Medical, Inc. (now part of Medtronic)

Co-inventor of the nitinol support and founder of Kips Bay Medical and Medical 21, Inc.

Manny Villafaña is the Founder, Chairman, & CEO of Medical 21, Inc.  Dr. Villafaña is globally recognized as a “Living Legend of Medicine.”  He is an award-winning USA Master Entrepreneur, a member of the Halls of Fame of Minnesota Business and Science & Technology.  He is the past founder of medical device companies that  have transformed the industry of cardiac surgery and improved the lives of millions.  Manny is also the recipient of an honorary Doctorate of Sciences degree from the University of Iowa.

Bio coming soon.

Mr. Khawar will share the story of Diality at Emerging Medtech Summit and will discuss partnering and investment opportunities.

Osman obtained his MD from the University of Glasgow and his MPH from Johns Hopkins. He is a Board-Certified nephrologist with a passion for Home Dialysis. He is an experienced Clinical researcher and entrepreneur who has run several businesses in the Dialysis industry including a Clinical Research company and several Dialysis Units in San Diego. He currently serves on the Palomar Health Foundation Board.

Mr. Rackliffe will share the story of Centerline Biomedical and will discuss strategic partnering and investment opportunities.

As CEO of Centerline Biomedical, Mr. Rackliffe brings more than 20 years of healthcare experience and executive management, spanning both medical device and pharmaceuticals industries, across both public and private sectors.  He has successfully led start-ups, as well as company divisions with over $2 billion in annual revenue.

As a growth catalyst, he has successfully launched more than 25 global life science products focusing on the needs of the patient and those that surround the patient/care environment.  In addition, he has led and closed multiple global business development deals to drive synergies and growth.  He believes that nothing is achieved without a strong team culture and takes pride in building teams that are both highly diverse and value inclusion.

Mr. Rackliffe received his MBA with high distinction from Joseph M. Katz Graduate School of Business, University of Pittsburgh and a duel major BS from Marquette University.

Dr. Aklog will be a presenter at the Emerging Medtech Summit and will share details on PAVMed's plans for growth and partnering/investment goals.

Lishan Aklog, M.D. has been the Company’s Chairman and Chief Executive Officer since its inception. Dr. Aklog has also served as a member of the board of directors of HCFP, Inc., a financial advisory and investment firm, since its inception, and as a co-founding Partner of both Pavilion Holdings Group (“PHG”), a medical device holding company, since its inception in 2007 and Pavilion Medical Innovations (“PMI”), a venture-backed medical device incubator, since its inception in 2009. Dr. Aklog previously served as Chairman and Chief Technology Officer of Vortex Medical Inc., a PHG portfolio company, from its inception in 2008 until its acquisition in October 2012 by AngioDynamics Inc. (Nasdaq: ANGO) for $55 million.

Dr. Aklog has been a consultant to Biomet Inc., now Zimmer Biomet (NYSE: ZBH), since 2009. He previously served as a consultant to AngioDynamics, from 2012 to 2016, Edward Lifesciences Corp. (NYSE: EW), from 2007 to 2012, On-X Life Technologies Inc. from 2009 to 2012 and Atricure Inc. (Nasdaq: ATRC) from 2007 to 2016. Dr. Aklog also previously served on the Scientific Advisory Boards of numerous leading medical device companies, including Medtronic, St. Jude Medical, Guidant Cardiac Surgery (now, Maquet Cardiovascular) and Cardiovations (then, a division of Johnson & Johnson).

Dr. Aklog is an inventor on 13 issued patents and over 30 patent applications, including the core patents of Vortex Medical’s AngioVac system and the patents for a majority of the Company’s products. Prior to entering the medical device industry full-time in 2012, Dr. Aklog was, from 2006 to 2012, Associate Professor of Surgery, Chief of Cardiovascular Surgery and Chair of The Cardiovascular Center at St. Joseph’s Hospital and Medical Center’s Heart and Lung Institute in Phoenix, Arizona. From 2002 to 2006, Dr. Aklog was Assistant Professor of Cardiothoracic Surgery, Associate Chief of Cardiac Surgery and Director of Minimally Invasive Cardiac Surgery at Mount Sinai Medical Center in New York. From 1999 to 2002, Dr. Aklog was Assistant Professor of Surgery at Harvard Medical School, Director of the Cardiac Surgery Research Laboratory and an attending cardiac surgeon at Brigham and Women’s Hospital in Boston.

Dr. Aklog received his clinical training in general and cardiothoracic surgery at Brigham and Women’s Hospital and Boston Children’s Hospital, during which he spent two years as the Medtronic Research Fellow at Harvard Medical School’s Cardiac Surgery Research Laboratory. He was then awarded the American Association of Thoracic Surgery Traveling Fellowship pursuant to which he received advanced training in heart valve surgery under renowned cardiac surgeons Sir Magdi Yacoub at Harefield Hospital in London and Professor Alain Carpentier at L’Hopital Broussais in Paris. Dr. Aklog is a co-author on 38 peer-reviewed articles and 10 book chapters. He has served on the Editorial Board of the Journal of Cardiothoracic Surgery since 2006. He is a member of numerous professional societies and has been elected to the American Association of Thoracic Surgery. He served on the Board of Directors of the International Society for Minimally Invasive Cardiothoracic Surgery from 2006 to 2009 and as President of the 21st Century Cardiothoracic Surgery Society in 2011. Dr. Aklog was recognized as one of America’s Top Doctors in the Castle Connolly Guide from 2002 to 2013. He serves as Chairman of the Boston ECG Project Charitable Foundation and the New York Executive Committee of Human Rights Watch. Dr. Aklog received his A.B., magna cum laude , in Physics from Harvard University, where he was elected to Phi Beta Kappa. Dr. Aklog received his M.D., cum laude, from Harvard Medical School. The Company believes Dr. Aklog is well-qualified to serve on the Board due to his extensive experience in founding and building successful medical device companies, his distinguished career as an academic cardiac surgeon, his recognition as a thought leader and innovator both as a surgeon and a medical device entrepreneur and his widespread relationships in the healthcare and medical device communities.

Mr. Altman will share the story of CorInnova at the Emerging Medtech Summit and discuss oppportunities to invest in or partner with the company.

William provides executive management oversight drawing on 25 years' of experience building healthcare companies.  Mr. Altman is a former McKinsey & Co. consultant, and co-founded two firms that grew to over $50M revenues, including one healthcare services company that grew to 500 employees. He has served on the boards of five growth companies, including a 7,000 employee NASDAQ listed company which increased its market capitalization from $0.5 billion to $1.5 billion during his tenure, when it was successfully sold.  Previously, Mr. Altman served as President & CEO of Kardia Therapeutics, a regenerative medicine company engaged in developing adult cardiac stem cells for use in heart failure therapy.  A native of New Ulm, Texas (pop. 500), Mr. Altman earned a B.S. degree in Electrical Engineering from Texas A&M University, an M.A. in Politics and Economics from Oxford University as a Rhodes Scholar, and an M.B.A. from Harvard Business School.

Kevin is a dynamic, energized, passionate and results driven medical device executive with Start-up, Mid-cap and Fortune 500 company experience that builds and leads high performing organizations by empowering others, creating a culture of collaboration, developing and executing strategic plans while improving efficiencies throughout the organization.

Bryan will share the Pristine Surgical story at the Emerging Medtech Summit and discuss partnering and fundraising updates. 

Mr. Lord works with start-ups and investors to bring new med-tech, high-tech, clean-tech, and software products to the market and to help companies scale. He has experience as an executive, entrepreneur, advisor, deal facilitator, and investor. 

Dr. Singh will share the Fist Assist story at the Emerging Medtech Summit and discuss partnering and fundraising needs.

Dr. Singh is a vascular/endovascular surgeon and entrepreneur with a strong understanding of current unmet clinical needs in vascular access markets. Founder of the Fist Assist Device which will help vein enlargement and fistula dilation.

John will share updates on Auctus Surgical and ZKR Orthopedics at the Emerging Medtech Summit and discuss the partnering and fundraising interests of both ventures.

Mr. Barrett is a seasoned healthcare executive with 25 years of experience in business building, fundraising, product development, sales and marketing, intellectual property, and regulatory affairs in both small and large company settings.

John is currently founder and CEO of ZKR Orthopedics, and early stage company focused on the development of a novel family of knee implants to address patellofemoral osteoarthritis, and Auctus Surgical, another early stage company developing a dynamic vertebral body tethering system to treat pediatric scoliosis with a non-fusion approach.

John previously founded CoAlign Innovations, a spinal implant company acquired by Stryker Corporation in 2014.  John led the company from early concept through multiple regulatory approvals and commercialization.  John raised $20M in funding and built the team to get through the successful exit to Stryker.

John had previous leadership positions at Abbott Vascular and Baxter.

Amit will share the Promaxo story at the Emerging Medtech Summit and discuss partnering and fundraising updates.

Dr. Vohra is a serial entrepreneur, business strategist and advisor to several healthcare and technology startups. Amit serves as a board member at Navaux and an advisor to Fanisko, Triocula and UnityDx.

Bio coming soon.

Matt will present Shoulder Innovations at the Emerging Medtech Summit and share investment/partnering opportunities.

Matt is an entrepreneurial business leader with 15 years of experience building and managing dynamic technology companies. He has a proven track record of successfully bringing innovative products and services to market. Prior to Shoulder Innovations, he was COO of Conpoto, and VP of Finance, COO and President of LeanLogistics.

Matt is also Managing Director at MD Capital Funds and a Director with Genesis Innovation Group where he invests in early stage medical device companies.

Mr. Persson will present Acarix and their CADScor® System at the Emerging Medtech Summit.  As the company is preparing for US market entry, he is exploring potential investment and strategic commercial partnering.

Mr. Persson, a Swedish native, is a highly engaged and dedicated professional with 30 years of experience in Medical Device Industry. This includes General Management/Senior Leadership, International Sales and Marketing for the entire EMEA region. His commercial career within Medical Devices started regional sales with IVAC Inc. (today within Becton Dickinson).  Since 2004 he has been in General Management roles, running direct affiliates in all aspects, including Sales, Marketing, Finance and related operations with companies such as Guidant (Director Marketing), Boston Scientific (GM Nordic Region), St Jude Medical (Director Marketing) Atos Medical (VP Sales and Marketing Europe).  

Acarix has developed CADScor® System, a unique device with an acoustic sensor and algorithm to assess cardiac blood flow rapidly, safely and non-invasively. CADScor enables early rule out of symptomatic patients with suspected stable Coronary Artery Disease at point of care. CADScor® is in an early commercial phase in Europe.  CADScor® is not approved for sales or commercial use within the USA.  Acarix is a European based company with the Headquarter in Sweden, the approval process for the US market has been initiated recently. 

Mr. Connell will share the story of NeuEsse at the Emerging Medtech Summit and discuss his current investment needs and potential partnering opportunities.

Joe brings more than 35 years of pharmaceutical and biotechnology sales, marketing and executive management experience. His career started as a Pharmaceutical Sales representative with Roche Laboratories. He has had roles of increasing responsibility, including as COO, President and CEO, of startup and specialty pharmaceutical companies with global responsibilities.

Joe has been instrumental in the launch of more than 25 major pharmaceutical products and devices. He has expertise in the areas of Dermatology, Wound Healing, Cardiovascular, Infectious Diseases, Gastroenterology, Oncology, Pain Management, Anesthesiology, and Diabetes. Joe has been involved in global efforts with aerosol, nasal and pulmonary drug delivery devices.

His career has enabled him to found or co-found seven companies, take one to a presently traded public company and help countless startups as a consultant, subject expert and interim CEO. He has worked with companies in Dermatology, Wound Healing, Orthopedics and Infectious Diseases.

Joe has presented at Rodman & Renshaw, OneMed Place, Southeast BIO, BIO-CEO, Stem Cell Meeting on the Mesa, Raleigh CED, NC Bio, Defense TechConnect 2018, SmarTemple Investments, Ben Franklin Technology Partners, Mid-Atlantic Diamond Ventures, Life Science PA Futures and many others.

Joe brings this expertise and drive to NeuEsse’s management team in the commercialization of this unique disruptive technology.

Richard will share the story of SANA Health at the Emerging Medtech Summit and discuss partnering and investment objectives.

With an MBA in Healthcare and Entrepreneurial Studies from Wharton Business School, Hanbury went on to become the founder of Sana, a device that allows anyone to have deep relaxation and pain relief anywhere in an average of 8-10 mintues. Sana has decades of research and anecdotal data and has just complete their first internal controlled trial. 

Mr. Cohen-Bacrie will share the story of e-Scopics at the Emerging Medtech Summit and will discuss capital needs and strategic partnering opportunities.

Claude is an entrepreneur in Medtech and founded two companies in the field of innovative ultrasound imaging. He was co-founder of SuperSonic imagine in 2005, and acted as executive vice president, Chief Technology Officer and Chief Operating Officer. In that role he brought the company through 4 rounds of funding and IPOed the company in 2014. The company has recently received a binding offer from Hologic.

In 2018, Claude founded e-scopics, a point of care ultrasound company, which aims at democratizing the role of ultrasound to ultimately all healthcare professionals. The company owns and develops proprietary technologies to allow dematerialization of ultrasound imaging architectures in order to put on the market, innovative devices with strong differentiation in the point of care market.

Claude was previously managing ultrasound research within Philips Research in charge of the collaboration with Philips Medical Systems. He is also former board member of Eye Tech Care, which develops High Intensity Focussed Ultrasound technology for glaucoma treatment and act as coach for several entrepreneur within M2Care.

Claude is a scientist by training, who further specialized in Signal and image processing and a thesis in Medical Imaging. His qualifications also includes an MBA from HEC, NYU Stern and the London School of Economics.

Mr. Klass will share the story of Sense Diagnostics at the Emerging Medtech Summit and will provide updates on important developments the company has recently made. He'll also discuss investment and strategic partnering interests.

Geoff has spent over 30 years building commercial organizations, from startups to global enterprises. He maintaines a deep healthcare and neuro innovation background.

Mr. Rocco will share the story of Biorez at the Emerging Medtech Summit and discuss strategic partnering and capital needs for the company.

Kevin is the CEO of Biorez, a medical device company developing bio-inductive implants for the $7B sports medicine market. He an experienced entrepreneur and expert in the field of tissue engineering, having raised $5M in seed funding for Biorez and coauthoring 19 peer-reviewed publications with 400+ citations.  Previously, he was the first full-time engineer at STR during the first clinical investigation of a synthetic bio-inductive scaffold for ACL reconstruction, and was a part of the first clinical investigation of a bio-inductive scaffold as a vascular graft while a graduate student at Yale University. 

At the Emerging Medtech Summit, Mr. Pradella will share the story of Greenbone Ortho and will be available to meet with potential investors and strategic partners.  

Lorenzo has a Masters in Biological Sciences obtained at Università degli Studi di Milano with a Postgraduate Qualification in Pharmacology (Ph.D. equivalent). More then 25 years experiences in R&D, Business Development and Venture Capital. He held various senior positions in multinational companies such as Zambon Group SpA and Catalent Inc (formerly part of Cardinal Health Inc.). Lorenzo established licensing and acquisition deals with pharmaceutical, biotech and medtech companies. General Manager of Zcube srl (Research Venture of Zambon Group) from 2008 Lorenzo developed collaborations and investments with major universities hubs in Europe, United States and Israel, as well as with Mission Bay Capital and the California Institute for Quantitative Biosciences (QB3), headquartered on the UCSF Mission Bay campus. Board member of biotech companies including SuppreMol GmbH when acquired by Baxter International Inc. for EUR 200 million in 2015. President of Italy HealthCare Licensing Group (ItalyHLG) 2010-2014 and Honorary President of the Business Development Academy since 2014. 

Nick will share the story of Strados Labs at the Emerging Medtech Summit and will discuss investment and strategic partnering opportunities.

Bio coming soon.

Matt was an EMT in Boston, MA for two years where he learned firsthand how hard it can be to diagnose a stroke with just a clinical exam. While attending the University of Pittsburgh School of Medicine and afterwards, conducted and published research on the difficulties of pre-hospital providers diagnosing stroke. He was part of the team that conducted the largest US study on identification of large vessel occlusive strokes in the pre-hospital environment. His years of work on this problem led him to create ALPHASTROKE.

Mr. Grecchi will share the story of Silk Biomaterials and will discuss investment and strategic partnering opportunities.

Bio coming soon.

Dr. Ben J. Lipps will share the story of Magforce at the Emerging Medtech Summit and will discuss strategic parntering and investment opportunities.

Dr. Lipps studied chemical engineering in the USA and earned his doctorate degree at the renowned Massachusetts Institute of Technology [MIT] in Boston. Dr Lipps was appointed to the Management Board of MagForce AG in September 2013.His career as manager began in the research departments at various companies, including at DOW Chemical, before switching to the Fresenius group in 1985, where he held various positions at Fresenius USA and Fresenius Medical Care North American until 2004. As Chairman of the Board, he led Fresenius Medical Care from 1999 to 2012 with a great deal of scientific and economic success.

Mr. Tas will share the story of SentiAR at the Emerging Medtech Summit and will provide updates on strategic partnering and investment opportunities.

Berk serves as the Chief Executive Officer and President of SentiAR. Berk has led development of emerging technologies and companies in Fortune 500, private equity, venture capital funded and privately held organizations. Prior to joining SentiAR he led the development of a novel Trans-aortic Valve Replacement technology into CE Mark studies at HLT Medical. In 2016, he played an integral role in the acquisition of Sensium, Oxford UK, a novel wireless monitoring technology. Prior to that he served in various leadership roles at Sunshine Heart developing a first of its kind, heart failure therapy and at Boston Scientific developing several novel therapies and technologies focused in Cardiac Rhythm Management. He holds an MBA from the Carlson School of Business at the University of Minnesota and a BS in Electrical Engineering and Physics from the School of Engineering at St Thomas University.

Mr. Elimelech will travel from Israel to share the story of Augmedics and discuss investment and strategic partnering opportunities.

Nissan is a visionary entrepreneur with 10 years' experience in various medical device markets. Founder and CEO of Augmedics, which develops a smart surgical system using Augmented Reality Head Mounted Display. Prior to Augmedics, Nissan worked at Medtronic in the spine surgery unit, and in Neopharm in the general surgery unit. In addition, Nissan co-founded and was the inventor of another medical device start-up company, Medizn, which has developed a smart surgical hernia mesh. Mr. Elimelech is a Bio-Medical engineer with an MBA degree. 

Dr. Shelton will share the story of PhotoniCare at the Emerging Medtech Summit and will discuss strategic partnering and investment opportunities with the company.

Ryan is a passionate problem solver and competent, experienced leader. He is an engineer by training who fell in love with entrepreneurship while at the University of Illinois.

Mr. Atria will share the story of nView Medical at the Emerging Medtech Summit and will discuss strategic partnering and investment opportunities.

Cristian has consulted and worked for Fortune 100, start-up and private equity owned companies (GE Healthcare, Fiagon GmbH, HealthTronics, nView medical). With nView medical, Mr. Atria has successfully secured seed funding from private investors, successfully obtained Small Business Innovation Research grants (SBIRs) from the National Science Foundation (NSF) and built a superb team.  Prior to founding nView medical, Mr. Atria worked 13 years for GE Healthcare. His last role was General Manager with Global Profit & Loss responsibility where he ran an acquired start-up in the field of surgical navigation (VTI) and integrated it with GE OEC. Mr. Atria has developed and launched three major image guidance platforms and obtained five 510(k) clearances.  Mr. Atria holds two Masters of Science in Engineering from Supelec, Paris and Politecnico di Torino, Italy and an MBA from Boston University in Boston, Massachusetts.

Jennifer is the CEO and Co-Founder of ExplORer Surgical. Jennifer founded the company with Dr. Alex Langerman as an MBA student at the University of Chicago Booth School of Business, where she received her degree with honors in Finance and Entrepreneurship. 

Previously, Jennifer was a Vice President at Park Lane Ventures, a healthcare-focused venture capital fund spun out of Essex Woodlands. Jennifer began her career as a consultant at Bain & Company in Chicago after graduating from Northwestern University.

Ben received a BS in Mechanical and Aerospace Engineering from the University of Virginia, where he focused on material science, biomedical engineering, and energy engineering. At the George Washington University, his work focused on new materials and 3-D printing for stem cell growth and orthopedic tissue repair. Dr. Holmes has been awarded several patents, published numerous journal articles, and contributed a chapter to the book Tissue and Organ Regeneration: Advances in Micro- and Nanotechnology (Pan Stanford Publishing, 2014). In addition to research, he has a strong record in entrepreneurship, having participated in the National Science Foundation’s I-Corps program on the local and national levels and VentrueWell’s ASPIRE program for medical device companies. Dr. Holmes has also demonstrated a strong early stage funding track record, bringing the company an National Science Foundation I-coprs grant, a Pediatric Orthopedic Society of North America research grant and most recently a Phase I SBIR award from the NSF. 

Mr. Lucas will share the story of Navigation Sciences at Emerging Medtech Summit and discuss capital and strategic partnering interests.

Alan has served in senior business development and marketing positions at development stage and emerging medical technology companies for more than 25 years. He has global senior management experience enhancing investor value, including execution of successful fund raising, IPOs, private placements and cross border M&A transactions,. His experience includes work at Alira Health, EnlightenVue, Simplicity Orthopedics, Abiomed, and Implant Sciences.  His experience includes work at Alira Health, EnlightenVue, Simplicity Orthopedics, ABIOMED, Implant Sciences, Kirschner Orthopedics and ACUFEX MicroSurgical.

Mr. Preston will share the story of Centese and will discuss capital needs and strategic partnering interests.

Bio coming soon.

Mr. Frick will share the story of ChemoTech at the Emerging Medtech Summit and will discuss investment and strategic partnering milestones.

ChemoTech is an R&D oriented publicly listed Life Science company based in Sweden. With more than 30 years of collected research and intellectual properties in the field of Electroporation and clinical research, ChemoTech has developed a new patent pending patient-specific Electroporation platform. A technology platform, called IQwave™, specifically designed to treat patients with larger bulk tumors that is difficult to treat with traditional cancer therapies. The first application built on this new innovative platform is already launched in India, Philippines and Kenya. The treatment protocol for this new device is called D-EECT and is used to treat none responsive Breast cancer, Head & Neck tumors and Sarcomas. Chemotech’s primary markets are India, South East Asia and Africa as patients in these markets often lack the availability to western cancer treatments combined with late diagnoses resulting in a high degree of incidence of large superficial tumor

About Mohan 
Born 1974 (Chengalpattu India)
Education and experience: BA, Marketing and Management, Lund University. 
Co-Inventor of the D-EECT Technology and IQwave™ Next generation of Electroporation Devices
20 years’ experience as CEO, Marketing Manager and Board Director in life science industry having had positions at SYSMEX, OnMeD International, Arjo AB and Getinge AB.
Current assignments: CEO & Board Director for Scandinavian ChemoTech AB
Non-Profit assignments: Member of the Advisory Board for Billion Minds Foundation 2009-2014.

Mr. Borbath will share the story of Synergia Medical and the Emerging Medtech Summit and will discuss business, investment and partering updates.

Attila Borbath's M.Sc. in Business Administration and Engineering from the UCLouvain followed by the CEMS Master's in International Management naturally brought him to pave his professional way in a technological start-up in the finance sector for 10 years. 

In parallel, he obtained his Airline Transport Pilot License. He was then convinced by the idea of joining an innovative technology start-up where he had the role of VP Sales and Marketing. In 2013, he moved to Synergia Medical that he co-founded. Well-travelled, multilingual and energetic, Attila has developed remarkable management, entrepreneurial, marketing, and business development skills. 

Mr. Klontz will share the story of New View Surgical at the Emerging Medtech Summit and discuss capital and partnering objectives for 2021.

Bryce is an accomplished global sales and marketing executive, having built and led commercial teams in the US, Europe and Asia. Most recently, Mr. Klontz was the Vice President of Commercial Strategy, Emerging Markets at Covidien, PLC where he led efforts to build commercial capabilities within the $1.5B+ Asia, Latin America, Emerging Europe, Middle East and Africa geographies. Mr. Klontz spent 14 years at Covidien in various leadership roles including Marketing Director in both the US and Europe, as well as 3 years as Vice President, Surgical Devices Business Unit, in Asia. Mr. Klontz also served as the global post-M&A integration lead for two of Covidien's most impactful acquisitions. Earlier in his career, Mr. Klontz played a pivotal role in the global launch of The CO2 Heart Laser System. Mr. Klontz received his MBA in marketing and finance from Carroll School of Management at Boston College and a Bachelor's degree from Northwestern University.

Mr. Merrick will share the story of NorthStar Medical at the Emerging Medtech Summit and will plans for growth, capital needs, and partnering objectives.

Steve, recently appointed as President and Chief Executive Officer, has 24 years of experience in the Biotechnology/Pharmaceutical/Life Sciences industries where he has held multiple executive positions with leading global companies, including leadership of Nuclear Medicine businesses.  He has extensive general management and corporate officer experience, as well as a proven track record of integrating science, engineering and commercial activities to drive complex projects to successful completion.  Steve also served in the Royal Navy as a Nuclear Submarine Officer, where he specialized in Navigation and Operations.

Steve received a BSc (Honors) in Engineering Science from the University of Exeter and an MBA from the London Business School, both in the United Kingdom.  He also completed the Nuclear General Course at the Royal Naval Staff College, Greenwich in the United Kingdom.

Mr. Marchand will share the NIDO story and discuss investment needs and development plans for NIDO at the Emerging Medtech Summit.

Bio coming soon.

Mr. Cathcart will share the story of AiM Medical Robotics at the Emerging Medtech Summit and will discuss strategic partnering and investment status.

Experienced Medical Device executive with a focus on commercial activities for both small and large companies.

Dynamic Sales leader with a strong track record of growth. Start-ups, organizational restructuring, product launches, Capital equipment and Disposables. Excellent relationships in Surgery, Interventional Cardiology and Interventional Radiology. 

Mr. LeDuc will share the story of Ortho Regenerative Technologies at the Emerging Medtech Summit and will discuss investment & partnering objectives.

Claude has accumulated 32 years of senior executive, CEO, COO experience with private and Fortune 500 medical device and bio-pharma companies. He has spent 22 years in the musculoskeletal market, having occupied senior positions with Genzyme, Biomatrix, Serono and BioSyntech. He has raised more than $50 million in public & private financings after taking BioSyntech public on the TSX-V exchange as its CEO in 2004. During his 5year tenure as BioSyntech CEO, he has worked closely with Ecole Polytechnique who is an active partner in the development of Ortho-RTi's proprietary platform, and was directly involved in the clinical and regulatory development of the BST-CarGel product which was later acquired by Orthopaedic giant, Smith & Nephew.

Mr. Dietiker will share the story of Medtor at the Emerging Medtech Summit and discuss their financing round and licensing/partnering interests.

Entrepreneur and Medical Device Executive with extensive experience and technological background in medical devices, start-up, growth and turn-around management. 

Dr. Mitchell will share the story of Novuson at the Emerging Medtech Summit and will discuss their financing objectives and strategic partnering plans.

Dr. Mitchell is a graduate of the University of Washington and he has been designing biomedical instrumentation and devices for approximately 20 years. Dr. Mitchell has extensive experience in biomechanics (soft tissue and orthopedic), tissue engineering, instrumentation, electronics, and mechanical design.

While at the university, Dr. Mitchell managed and conducted research in multimillion dollar DARPA projects where he developed relationships with medical industry leaders. He has conducted research in biomechanics, tissue engineering, acoustic hemostasis and high intensity focused ultrasound (HIFU) for tumor treatment. Dr. Mitchell has been involved in helping HIFU gain recognition in the clinical setting and has led research teams in conducting application studies.

Mr. Muldoon will share the story of FAST BioMedical at Emerging Medtech Summit and will discuss investment and strategic partnering opportunities.

Joe leverages 30 years of experience, from technology start-up organizations to publicly traded multi-national companies. He has worked with many high-growth entrepreneurial companies, occasionally serving as Angel Investor and CEO. Joe has advised select medical technology companies, including TGX Medical, Vasc-Alert, Trust Bearer Labs, and Geist Pharmaceuticals. Previously, he was President and CEO of FirstMile Technologies, a start-up broadband provider he led through its sale. Prior to that, he served as President of Brightpoint North America, a publicly traded Fortune 500 wireless company that grew to $750MM under his leadership. He has also held executive general management positions at MacMillan. He started his career as a CPA in Ernst & Young’s Entrepreneurial Services practice. Joe has a Bachelor of Science in Business from Indiana University’s Kelley School of Business, where he is a panelist for various MBA programs.

Dr. Klock will represent QT Imaging at the Emerging Medtech Summit.

Dr. Klock received his medical degree at Tulane University, his medical training at the University of California San Francisco and Massachusetts General Hospital. He is a board-certified Internist and Hematologist-Oncologist and practiced medicine and did research at the University of California San Francisco from 1970-1982. Since 1982 he has been involved in the start-up of seven medical companies. In these companies he has worked alongside many talented people to develop and bring to market: a novel cancer treatment, the first rapid AIDS test, comprehensive tests for detecting metabolic diseases of children, several drugs for treating genetic diseases of children, and a novel medical imaging device. He continues to be involved in introducing innovative concepts into medical practice and is on the board of several medical companies. Dr. Klock has over 70 peer-reviewed medical and scientific publications and 11 granted US Patents. 

Mr. Daniels will represent Stroma Medical at Emerging Medtech Summit where he will share updates on the company and discuss investment and strategic partnering needs.

Doug Daniels grew up with seven brothers and sisters in Bloomfield, NJ. He met his wife when they were both children.

Mr. Daniels attended high school in Medfield, MA, where he served as captain of the varsity basketball and track teams. He was a state finalist in basketball and a two-time league All Star and two-time state Honorable Mention All-Scholastic Player. He was also a gold medalist in the 4X 880 state championship relay track team.

Mr. Daniels graduated with honors in Special Education from Bridgewater State University in Massachusetts. While at Bridgewater, Mr. Daniels continued to indulge his passion for athletics. He played varsity basketball and volleyball, served as captain of the basketball team, and was named ECAC, Division III, Player of the Week several times. Before graduating from Bridgewater, Mr. Daniels joined the full-time faculty at Tri-County Regional in Franklin, MA, where he served as assistant football coach and head varsity basketball coach, pursuing his joint passions for teaching and sports.

In 1981, Mr. Daniels hung up his jersey and turned his competitive passion to the business world. He began his business career as an NASD-licensed broker with AXA Equitable, where he earned Rookie of the Year as a first-year representative. He then joined Johnson & Johnson as a territory manager and sales trainer in their Patient Care division, where he was eventually awarded the President’s Club honor as a top sales performer and promoted quickly through the company ranks.

Mr. Daniels was then recruited by Boston Scientific Corporation to serve in its MicroVasive division. Mr. Daniels enjoyed a long and successful career at BSC, honored early on as Representative of the Year and then promoted to Trainer, Product Manager, Marketing Manager, Director of Marketing, Vice President of Sales and Marketing, Vice President and General Manager of that division and then International Vice President of Urology and Endoscopy. Under his management, the MicroVasive became BSC’s fastest growing and most profitable business division. Mr. Daniels also contributed significantly to the BSC’s research and development efforts, developing several patented technologies during his tenure with the company.

After 15 years with BSC, Mr. Daniels wanted to return to the start-up environment. He became Vice President of Syntheon, a medical device incubator based in Miami, FL, which led to his becoming CEO of VeinRx, a Syntheon-incubated start-up. After building VeinRx into a viable business, Mr. Daniels joined HydroCision as President and CEO, which he turned around and led to multiple successful licensing exits. Mr. Daniels then founded Coopers Hawk Consulting to provide consulting services to medical device start-ups and university technology transfer departments. Mr. Daniels also served on the Board of Directors of Custom Spine, where he negotiated an exit at several times revenues.

Ben has more than 25 years of medical device experience over six startups as CEO, CCO and Vice President of Marketing & Business Development. He co-founded InnerSpace Neuro, raising $10 million in Series A financing.

An entrepreneur, engineer, inventor, Tamer currently serves as our President and Chief Executive Officer. Tamer co-founded Aspect in 2013 and has played a leading role in our overall corporate, business, and technology development. Under his leadership, we have secured significant funding, entered strategic collaborations with best-in-class pharmaceutical and biotechnology companies, and developed our commercial products. In his previous appointment as Chief Technology Officer of the company, Tamer drove the innovation and development of the company’s core technologies and intellectual property. 

As a leader in the field of 3D bioprinting, he has been invited to speak on this topic at venues ranging from TEDx to industry, scientific and executive conferences. In 2017, he was awarded BC's Top 40 under 40 award for demonstrating excellence in business, judgement, leadership, and community contribution. Tamer serves on the Board of Directors for ACETECH, a non-profit training and mentoring organization for CEOs of technology and life sciences companies, and on the Board of Directors for The Stem Cell Network, an organization focused on building Canada’s stem cell and regenerative medicine research sector. 

Tamer holds a B.A.Sc. in Biomedical Engineering and M.A.Sc. in Electrical and Computer Engineering from the University of British Columbia.

Bio coming soon.

Mr. Whitman will share the story of Micro Interventional Devices at Emerging Medtech Summit and will discuss strategic partnering interests.

Michael Whitman is the founder and CEO of Micro Interventional Devices, Inc. (MID). Michael has over 30 years of medical device experience at market leading firms including, Johnson and Johnson, Olympus, Synthes and Power Medical Interventions. He previously was the founder and CEO of Power Medical Interventions (NASDAQ; PMII), which was acquired by Covidien Ltd. in 2009. Prior to founding PMI, Michael served in numerous management positions at Johnson and Johnson during his 13-year tenure including Vice President of Sales, Director of Sales and Marketing, Product Development and Product Management. He is the named inventor on over 35 US and foreign patents. He received his A.B. in Business and Economics from Lafayette College and completed graduate work at Wharton, University of Michigan, Harvard Executive Education, and Rutgers University.

Raj has extensive experience in pharmaceutical science, nanoparticle drug encoding systems, and clinical risk management programs for specialty biological pharmaceuticals. As a registered pharmacist and an expert in strategic bio-science management, he has led the development of innovative pulmonary oncology adherence programs for some of the largest life science companies. With five published nanotechnology patents, Raj is the inventor of Canary’s breath decoding technology.

Mr. Liu will share the Vena Vitals story at the Emerging Medtech Summit and will discuss investment and strategic partnering opportunities. 

Ray is an executive leader in healthcare technology, with expertise in building, launching, and running products and services for both startups and multinationals. Prior to Vena Vitals, he ran product and operations for Ediom, where he created hospital decision support tools that led to the company's acquisition by Vizient, Inc. Ray also led product for Socialwellth, where he directed the development and launch of a consumer health engagement platform that was rolled out to 15.2M users, leading to the company's acquisition by Cigna. 

At Siemens, Ray developed strategies, turnaround plans, and new market entries for the healthcare, energy, and industrial business units, and at GE Healthcare, he led the global launch of patient vital sign monitoring devices from China to the rest of the world. In addition to co-founding and running Vena Vitals, Ray also serves as an advisor to MDstewardship, a telemedicine company focused on antimicrobial stewardship. Ray holds an MBA from Harvard Business School, an MS from the University of California at Berkeley, and a BS from the University of Illinois at Urbana-Champaign. 

Curtis is Chief Executive Officer of nRichDX and a member of its Board of Directors. William joined nRichDX in July 2015 and brings over 30 years of experience in the healthcare industry. He has exclusively been involved in healthcare business development and healthcare services since 1983.

Prior to joining nRichDX, William was the co-founder, Chairman and Chief Executive Officer of CBLPath Holdings Corporation, a specialized anatomic pathology and molecular laboratory that under his leadership experienced organic, profitable revenue growth from $4MM to $85+MM. Previously, he was the founder and Chief Executive Officer of MLC International and The Hillside Group, healthcare financial and business development companies.

Mr. Sharan will share the story of CellMax Life at the Emerging Medtech Summit and share details on their current capital raise and strategic partnering interests.

Atul co-founded CellMax Life in 2012, applying semiconductor industry principles to a proprietary Circulating Epithelial Cell Bio-Mimetic CMx platform to develop affordable and quantitative blood-tests for Early Cancer Detection and Treatment. He was motivated to start CellMax as two members of his family had been diagnosed with cancer – one of them was diagnosed with breast cancer within two weeks of receiving a conclusively negative mammogram. Atul is a veteran of the high-tech industry with experience as an engineer, serial entrepreneur, CEO and angel investor. Previously he was also resident at Mohr-Davidow Ventures and Artiman Ventures. He specializes in identifying unmet market needs and matching them with early-stage technologies to achieve dramatically better results than prevailing standards. He has done that successfully multiple times: AutoESL (acquired by Xilinx); ClearShape Technologies (acquired by Cadence), Numerical Technologies (Nasdaq IPO; acquired by Synopsys); Ambit Design (acquired by Cadence). Atul holds a BS in Engineering from IIT-India; MS in Engineering from UH, Texas and an MBA from UC-Berkeley.

Bio coming soon.

Mr. Shah will share the story of Nephrodite at Emerging Medtech Summit and will discuss partnering and investment opportunities.

Dr. Nikhil L. Shah currently serves as the System Chief for Minimally Invasive and Robotic Surgery at Piedmont Health Care based in Atlanta, Georgia. Dr. Shah has performed thousands of minimal access and robotic procedures with specific expertise in Genitourinary Oncology and urinary tract reconstruction. In addition, his interest and expertise in digital Surgery, intelligence, advanced-integrated imaging as well as automation as they apply to the patient-care continuum define his passion as a progressive Physician Leader.

Dr. Shah completed his undergraduate training at the University of Michigan and Medical School at the Kirksville College of Osteopathic Medicine. In medical school, Dr, Shah received a highly coveted research award funded in part by the National Institutes of Health. His training in General Surgery was at the Henry Ford Hospital in Detroit and followed with subspecialty training in Robotics, Laparoscopy and Urological Oncology at the Vattikuti Urology Institute at Henry Ford Health Systems in Detroit. During residency, Dr. Shah additionally completed a National Institutes of Health - National Institute of Diabetes and Kidney Urologist-Scientist Research Fellowship at the University of Michigan in Ann Arbor. Concurrently to his time in the laboratory, he completed a Master’s degree in Health Management & Policy at the University of Michigan’s School of Public Health and the Ross School of Business.

Dr. Shah is the recipient of numerous awards and has authored many peer-reviewed publications. He is acknowledged as an established leader in minimally invasive surgical applications. He holds an adjunct Associate Professorship at the Georgia Institute of Technology. Dr. Shah has made several appearances on CNN with Dr. Sanjay Gupta regarding Robotic Surgery and Men’s Health. In addition, Dr. Shah serves as an active advisor to the medical technology industry and the financial sector involved with innovative technology, medical devices, simulation and new surgical training applications.

Dr. Shah’s continues translational efforts by bridging the gap between health care issues, science and medicine. He speaks about the changes in health care from the perspective of a Physician Leader focusing on improving quality through metrics, analytics and outcomes analysis. Dr. Shah also continues to receive extramural funding in an effort to increase complimentary, preventive and advanced technology therapies to his patients.

Dave was preparing to begin a surgical residency when he was confronted with the need for the GraftWorx device. While researching a possible solution, he invented the GraftWorx technology and currently leads the company. 

Experienced President with a demonstrated history of working in the information technology and healthcare industry. Strong business development professional with a Doctor of Philosophy (Ph.D.) focused in Biomechanics from University of Wisconsin-Milwaukee. 

Ted Bird has over 35 years of global commercial experience in the medical device arena, including 30 years in the spine industry specifically. He led global marketing, medical education, and business development at Medtronic Sofamor Danek, and served as VP of Spine Arthroplasty Education at Depuy Spine/Johnson & Johnson, President of Orthofix Spinal Implants Division, and Non-Executive Chairman of the Board at Apifix. Additionally, he served as Chief Commercial Officer at Titan Spine and founded Bird Medical Group, a strategic consulting firm. Ted is currently on the Board of Bio2 Technologies, Inc. He graduated from Brown University with bachelor’s degrees in International Relations and Political Science.

Dr. Wood has 20+ years of experience championing innovative clinical solutions to the marketplace, from concept to revenue.

Dr. Wood most recently held the position of Executive Vice President of Marketing and Technology for Vital Images, an innovative advanced visualization software company. Prior to Vital Images, Dr. Wood served as VP of marketing at R2 Technology (now Hologic), where she championed the development, regulatory approval and commercial release of the first FDA approved (PMA) software product for the automatic detection of lung nodules in both diagnostic and screening chest CT examinations.

Dr. Wood received her Ph.D. from the Johns Hopkins Medical Institutions, School of Hygiene and Public Health. Her Ph.D. work combined quantifying three-dimensional lung structure with changes in lung function using high-resolution CT imaging. She also holds a Master of Science degree in Biomedical Engineering from Duke University, and a Bachelor of Science in Engineering from the University of Maryland, College Park.

Dr. Wood has been issued six patents in the field of computer-aided detection and quantitative imaging; authored numerous book chapters, peer-reviewed papers, abstracts, and served as a speaker at numerous conferences in the area of three-dimensional imaging of the thorax, quantitative imaging and computer-aided detection.

An experienced innovator focused on providing creative insight and sound financial reasoning to deliver technological and strategic solutions to client's toughest business challenges.

Specialties: Life sciences and materials science research, Data analysis, Intellectual Property, Business development 

35+ years experience in biotech/pharmaceutical industry.  Led multiple companies from development stage to commercialization or M&A. Multiple Board positions.

In addition to holding the CEO role for EBT, Mr. Carlton is also a Co-Founder and General Partner at Guide Medical Ventures, a seed investment and management consulting firm.  Prior to EBT, Mr. Carlton was President & CEO of HUINNO, Inc., a digital healthcare platform company focused on improving the management and costs of hypertension through wearables and software.  Prior to HUINNO, Mr. Carlton held multiple positions at Boston Scientific Neuromodulation including Director of New Therapy Development (focused on Pain, Deep Brain Stimulation, Overactive Bladder, and other areas).  Mr. Carlton joined Boston Scientific through the acquisition of Intelect Medical where he was Co-Founder and VP of Product Development.  Prior to founding Intelect, Mr. Carlton also held various roles at Medtronic where he was co-inventor of the InterStim tined lead and developed InterStim II for OAB.  He also served as Director of Engineering at Texcel Medical (now Cirtec Medical).  Mr. Carlton holds over 40 patents around electrical stimulation products and therapies.  He has dual B.S. degrees in Biomedical Engineering and Engineering Mechanics from The Johns Hopkins University and an MBA from Boston University.

In January 2020, Jeff was appointed CEO and President of ChipCare and serves on its board of Directors. ChipCare is a pre-revenue medical device development company based in downtown Toronto. The company is developing a unique point-of-care in vitro diagnostics platform for sexually transmitted infections (STIs) which will enable physicians and clinicians to provide true test and treat care options for their patients, significantly enhancing the overall quality of patient care while reducing healthcare costs. Molecularly accurate diagnosis is available within thirty minutes of testing and can be performed in a nationwide pharmacy, STI or urgent care clinic or university health center, such that the patient can leave with appropriate prescription medication as well as an accurate diagnosis. The diagnostic capabilities of the platform are so precise that trial and error prescriptions often associated with anti-biotics can be avoided with the right antibiotic being prescribed for the right strain of infection. 

Clark E. Tedford, Ph.D. is a co-founder of LumiThera and has served as President and CEO since the formation of the Company in 2013. Previously Dr. Tedford was Vice President and Chief Science Officer at PhotoThera, a leading LED/laser company from 2010-2012. Prior to PhotoThera, Dr. Tedford was at Omeros from 2003-2010 as Vice President, Pharmaceutical Research. Prior to Omeros, Dr. Tedford was President of Solentix, Inc. During Dr. Tedford’s 30 years in the pharmaceutical and medical device industry, he has held several scientific and executive management positions from 1993-2003 including Executive Vice President of Research and Development for Gliatech, Inc. Prior to that Dr. Tedford was at Schering-Plough Research Institute as a Principal Scientist. Dr. Tedford earned his Ph.D. in pharmacology from the University of Iowa and completed his post-doctoral work in the Department of Pharmacology at the Loyola University Medical School.

Bio coming soon

Co-founder & CEO, Claude has more than twenty years of global experience in the Health Care industry in product & market development in pharmaceuticals & vaccines (Merck & Novartis). With extensive sales & marketing experience at the global and market level, including product launch, Claude led HPV vaccine blockbuster Gardasil regulatory, market development & commercial launch efforts. He also developed MenB vaccine, Bexsero, scientific platform, product profile & market development leading global marketing efforts through EMEA filing.

Angela is an experienced neurologist and prolific entrepreneur who has developed one of the most innovative brain stimulation technologies within the last decade.

Throughout her 25-year career, Angela has successfully represented medical companies in a variety of business transactions including licensing agreements and M&A deals with Pfizer, inVentivHealth Inc. and others.

As founder and CEO of Precisis AG in Heidelberg, Angela now offers a minimally invasive precise and personalized neurostimulation device that eases out the suffering of people with epilepsy.

Bio coming soon.

Associate Professor Andrew McDaid founded OPUM after years of world leading R&D and market insights. He is an internationally renowned expert and has led a large research team in medical robotics, wearables and AI. To date he has been awarded millions of dollars in research funding over ten years, including from US Department of Defense. As a sports enthusiast Andrew was patient zero after tearing his MCL (not for the first time). His knee was the first set of OPUM patient data collected.

Jerry brings more than 30 years of executive leadership in medical technology companies. In addition to starting Harbor in 2011 and building the corporate infrastructure, Jerry Mezger has gained FDA approval, Medicare reimbursement, and US government contracts for Harbor’s first product, Architect.

Prior to Harbor, Mr. Mezger has led successful turnarounds and acquisitions of several companies as CEO including Neomend (now part of CR Bard), InterTherapy (now part of Boston Scientific), SenDx Medical (now part of Radiometer), EndiCOR Medical (now part of Covidien), Arbor Surgical (now part of Medtronic), and Cardiovascular Devices, Inc. (now part of 3M).

Jerry holds a Bachelor’s degree from Northern Illinois University.

Cody is a bioengineer and entrepreneur that has focused all of his career on bringing new health technologies to physicians and patients. Most recently Cody led commercial efforts for a Silicon Valley medical device screening startup and held BD and commercial strategy roles at Genentech.

Vadim Gurevich, CEO of GLW Medical Innovation (“GLW”), will represent his company at the Emerging Medtech Summit to discuss not only GLW’s latest R&D initiatives, but also their investment and strategic partnership needs.  GLW is a medical device incubator focused on the design and development of cost-effective, high-margin implant and instrument solutions in various segments of the orthopedic market. They commercialize their products through exclusive distribution and education agreements with carefully selected sales organizations.

Mr. Gurevich has an extensive business career with over 19 years of leadership experience in medical technology.  He has a documented record of success spanning a broad spectrum of disciplines, including orthopedic trauma, foot & ankle, urogynaecology, general surgery and neurosurgery with extensive M&A, licensing, and post-acquisition integration expertise. His career encompasses a series of executive and senior decision-making positions at Stryker Orthopaedics, Integra LifeSciences, Synovis Surgical (Baxter BioSurgery), and Gyrus Medical (Olympus).

Mr. Gurevich is also President & CEO of Novastep Inc., a US sales and distribution company focusing on products that treat conditions affecting the bones, joints, and soft tissues of the foot and ankle. He holds similar titles at Innov8ortho LLC, a sales distribution company specializing in musculoskeletal trauma injuries, specifically hip fracture care products.

Todd Moseley is often quoted as coaching his employees to “be brilliant in the basics”, a philosophy that helped him to build one of the most successful orthopedic distributorships in the country. He launched the sales careers of over 100 sales representatives and was responsible for annual sales that exceeded $50 million. Many of his business models for distribution and marketing have been implemented by industry leading companies, some with revenues in excess of one billion dollars.

Todd has built meaningful relationships with key opinion leaders and executives in the orthopedic and spine markets over the past 25 years. Known as a dynamic, well-rounded business leader, he has a solid history of maintaining quality customer and employee relationships and providing exceptional customer service and value.

Todd is driven by the pursuit of excellence, both in work and in his personal life. He graduated from Campbellsville University with a Bachelor of Science degree in Business Administration. While attending the university on a baseball scholarship, he displayed a competitive spirit and motivation that he still employs today in all aspects of the day-to-day operations at Spinal Simplicity from spearheading fundraising to participating in product design. Todd’s team approach to leadership helps to implement a strategic business and marketing blueprint, streamline operational efficiency, and drive growth for Spinal Simplicity in the US and global marketplace.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Dushyanth lead the Acute Care Franchise within Dr. Reddy’s innovation business for several years. His responsibilities included the commercialization strategy of acute care products, which was the company’s highest value portfolio. He has had a proven track record in product conceptualization, invention, development, and licensing of products and devices across a number of therapeutic areas. He was responsible for the entire US branded sales and marketing organization, while also managing the corporate development and M&A function. He also held senior leadership roles across portfolio optimization, alliance management, and strategic planning.

Bruce Lichorowic is a highly accomplished entrepreneur and chief executive in the medical industries.

Former Positions of Note:

• President & CEO, Trak Surgical
• Managing Director, BlueFire Capital Partners
• President & CEO, Dynaptics Corporation

Laura joined RMI in July 2020. Prior she served as Vice President & General Manager of Envista following Danaher’s IPO of the business and led the Global Commercial Operations Department of Nobel Biocare Systems, another Danaher Operating Company. Laura has held senior executive roles with full P&L responsibility at Nellcor, Nellcor Puritan Bennett and Mallinckrodt. She held President roles at Tyco, Covidien, Stryker, and Acelity.  She has specific experience in respiratory monitoring technologies and an education and clinical background in intensive care patient management.

Peter brings more than 20 years of experience in the medical device and biopharmaceutical industry.

Prior to VCI, Peter served as the U.S. commercial vice president at Cordis.  In addition, Peter has held senior sales roles at St. Jude Medical Corporation, AGA Medical Corporation and Covidien Healthcare (formerly Tyco Healthcare), among other leading health care companies.

Peter has proven experience driving commercial growth; building and leading diverse organizations of over 300 individuals, managing revenues exceeding $500 M and representing product offerings with C-level administrators. Peter received a Bachelor of Arts in Economics from the University of Massachusetts and completed the Columbia University Executive Management Program

Ziad Rouag is an Operational Executive and Entrepreneur in the Medical Device Industry advising leading incubators and start-ups. Ziad is an advisor to several medical start-ups and resides in San Francisco and Paris.

Prior to establishing ORAN consulting and joining Biomodex as President and CEO, Ziad served as Head of Toxicology, Pharmacokinetics, Regulatory, Clinical, Data Management and Statistics at JUUL Labs a venture funded start-up that developed a breakthrough nicotine delivery system (Altria acquisition). Previously, Ziad served as Vice President, Pre-clinical, Regulatory and Clinical Affairs for PQ Bypass (Fogardy Institute for Innovation incubation), a venture funded start-up that developed a breakthrough endovascular arterial venous bypass system, spearheading a highly successful clinical trials and EU launch and setting the ground for a US IDE. Ziad further served as Vice President, Pre-clinical, Regulatory, Quality and Clinical Affairs for Altura Medical (Lombard Medical acquisition), a venture funded start-up that developed a modular endograft for treating complex abdominal aortic aneurysm. Prior to that, Ziad held several senior positions including Vice President, Regulatory, Quality and Clinical Affairs at Auxogyn (Stanford Byers Center for Biodesign incubation - Progyny Merger) and Avinger (IPO (AVGR) NASDAQ).

Further positions included, Director positions with Johnson and Johnson (Codman) and Evalve (Foundry Group incubation - Abbott acquisition). Previously Ziad held several Regulatory and Legal positions with Guidant (Abbott acquisition), Novartis and a MedDevice Plaintiff Legal Committee, focusing on medical device class action litigation.

Ziad is fluent in several languages, has lived in several countries and holds B.S. and B.A degrees in Biology and Economics and a Juris Doctorate Degree. Ziad is admitted to practice law in the United States. 

Omar M. Khateeb is a marketing leader based in Silicon Valley.  He is a strategic partner with LSI and thought leader within the medical device industry.

He has developed marketing strategies at two publicly traded surgical robotic companies through their IPOs as well as co-founded and successfully launched a consumer product for men’s fashion.

Having successfully crowdfunded and launched a consumer product, Omar brings his knowledge of B2C marketing through digital channels to a B2B world.

He is known for his strategies using consumer psychology across various digital mediums to guide healthcare companies in adapting to newly connected markets.

In his spare time, he enjoys teaching, mentoring young professionals, and donating his marketing expertise to non-profits. He also spends time speaking at various industry conferences on topics around digital marketing, business development, and market engineering.

You can follow with him on Facebook, Instagram, Twitter (@OmarMKhateeb) or Youtube (Mind Loom with Omar M Khateeb). 

Brian K. Hutchison is chairman and CEO of Catalyst OrthoScience Inc. He is a seasoned veteran of the healthcare industry, with more than 30 years of experience in medical devices, biotechnology and orthopedics. He has successfully led healthcare companies from start up to sustained, profitable growth with expertise in operations management, product development, turnaround strategy, team leadership and revenue growth.

Prior to Catalyst, Hutchison served 15 years as CEO of RTI Surgical Inc. (NASDAQ: RTIX). At RTI Surgical, he grew annual revenue from $55 million to $300 million, positioning the company as a leader in advanced biologic products. As CEO, Hutchison successfully merged RTI Surgical with Tutogen Medical in 2008 and in 2013 acquired Pioneer Surgical Technologies. Over his tenure, he secured multiple rounds of financing that included a $25.8 million investment in 2002 and a $22.2 million investment in 2005.

Before RTI Surgical, Hutchison held various positions at Stryker Corporation, including serving as vice president of worldwide product development and distribution, senior vice president and chief operation officer of the Howmedica Osteonics Division and president of the Stryker Medical Division.

Hutchison serves on the boards of directors of Zavation Medical Products and the University of Florida Research Foundation.He received a bachelor’s degree in accounting from Grand Valley State University and attended Harvard Business School’s Program for Management.

Mr. VeLure has extensive experience, and a track record of  consistent success, as a senior executive and veteran of the medical device and digital healthcare industries.  Most recently, Mr. VeLure was SVP, Corporate Development at Medibio Limited, a publicly traded, digital health company that provides objective assessment tools for mental health disorders.  Mr. VeLure founded Neurotech NA, Inc., a neurostimulation company that commercialized devices to accelerate non-surgical and post-operative rehabilitation. Serving as its CEO, he completed the sale of Neurotech NA to Theragen in 2015.  Mr. VeLure served as the Senior Director of Marketing and Business Development for Compex Technologies, Inc. managing both a direct and distributor based sales organization, and securing OEM supplier and product licensing agreements for both the US and international markets.  Prior to this, he was Director of Sales and Marketing for American MedTech, Inc., a Urology company that distributed FDA Cleared, devices for Erectile Disfunction and Incontinence.  Mr. VeLure has a BA double major in Economics and Business Administration from Augustana College in Sioux Falls, SD.

Medical technology entrepreneur. Formerly management consultant at Monitor Group, focused on medtech commercialization, and Senior VP of Marketing & Strategy at ConforMIS. BA from Harvard and MBA from Harvard Business School.

Kevin A. Richardson, II joined the Company as chairman of the board of directors in August of 2005. Mr. Richardson founded Prides Capital LLC and Prides Capital Partners LLC in January 2004 where he is Managing Director. Prides Capital LLC and Prides Capital Partners LLC specialize in strategic block, active investing in small-cap and micro-cap public and private companies. From April 1999 until the end of 2003, Mr. Richardson was a partner at Blum Capital Partners, a $2.5 billion investment firm. Between May 1999 and September 2003, Mr. Richardson was the lead public partner on 18 investments.

Prior to joining Blum Capital, Mr. Richardson was an analyst at Tudor Investment Corporation, an investment management firm. Previously, Mr. Richardson spent four years at Fidelity Management and Research where he was the assistant portfolio manager of the Fidelity Contra Fund, a registered investment company. Mr. Richardson also managed Fidelity Airline Fund, the Fidelity Aerospace and Defense Fund, and performed research and analysis in a variety of industry sectors (computer services, business services, media, financial services, and healthcare information technology).

Mr. Richardson is also a member of the board of directors of As Seen On TV, Inc., a publicly traded multichannel distributor of As Seen On TV products and Pegasus Solutions, Inc., a travel technology company and was previously a board member of Healthtronics, Inc. and QC Holdings, Inc. Mr. Richardson received an undergraduate degree from Babson College and an M.B.A. from Kenan-Flagler Business School at the University of North Carolina.

Mr. Perry brings 25 years of experience in medical device start-ups including having led or contributed to multiple exits, venture financings, an IPO, 16+ medical product introductions, and 20+ business development deals.

A member of the Company’s Board of Directors since December 2011, he was the founding CEO of Amedica Corporation (www.amedica.com), an orthopedics implant company utilizing its novel Silicon Nitride platform technology. While at Amedica, Dr. Khandkar led the company through the various stages of its development including the invention and co-authoring of its core patents, the design and implementation of its state of the art manufacturing facilities, regulatory clearances and commercialization of its ceramic products, including the first ever ceramic spinal implant cleared for humans by the FDA. In 2010, he founded Bloxr, a Salt Lake City radiation protection company that was sold to an industry buyer in September 2014. Since early 2015, he has been consulting with Xenocor, a startup founded on a novel laparoscopy platform. Dr. Khandkar’s 27 years of experience in advanced technology companies also spans management of finance, regulatory clearances, strategic planning and business development. He is an inventor on 35 U.S. and international patents. He is an Adjunct Associate Professor at the University of Utah. Dr. Khandkar earned his Ph.D. in Materials Science from Arizona State University.

A 2013 graduate of MIT with a BS in Mechanical Engineering, Adam co-founded Vicarious Surgical in 2014 with Sammy Khalifa. Since 2010, he’s been an Emergency Medical Technician (EMT) on an ambulance in Cambridge serving the needs of the MIT community.

Bio coming soon.

Bio coming soon.

Carol Burns is a serial entrepreneur with extensive experience in the cardiovascular sector. She is the founding CEO of Cagent Vascular. Previously she served as the founding CEO of Intact Vascular, the first company formed with her partners Robert Giasolli and Peter Schneider, MD. She has proven success raising capital, recruiting high performance management teams and achieving milestones in a capital efficient manner. Ms. Burns was an integral team member in Embrella Cardiovascular (sold to Edwards LifeScience’s), Animas Corporation (acquired by Johnson & Johnson), Ventrica (acquired by Medtronic) and Guidant Corporation. Carol is a registered nurse, bringing in-depth, clinical expertise to Cagent Vascular. Ms. Burns serves on the Penn Health-Tech Strategic Advisory Board.

John joined SOMNERA as President and CEO in 2016, and is a 30 year veteran of the Medical Device Industry. John has held leadership roles in nearly every function, from sales to operations, where he has led numerous products and businesses through development and transformative growth. Prior to joining SOMNERA, John was the Chief Operating Officer of USGI Medical, where he led the development and commercialization of a breakthrough non-invasive surgery platform. He has held senior executive and management roles for several medical device manufacturers such as B. Braun Aesculap, Applied Medical, and U.S. Surgical. John also serves as Chairman and Co-Founder of Retraction Ltd., a Hong Kong-based innovator in minimally invasive surgery. John is named on over 20 US and foreign patents, and earned his MBA with honors from the University of Virginia’s Darden School of Business. Recently, he won OCTANe’s “Elevator Pitch” contest representing Somnera as a LaunchPad finalist in 2017, and was selected to be the Master of Ceremonies at the 2019 Medical Technology Innovation Forum (MTIF), Orange County’s largest annual Medtech meeting.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Reinhard Krickl is the CEO of Phagenesis®. He has extensive experience in sales & marketing and new therapy development within the medical device industry, including 14 years as a “corporate entrepreneur” at Medtronic.

Alongside his industry experience he has a MBA and a MSc in Electrical and Electronics Engineering.

Don brings decades of informatics and healthcare leadership to Clarigent Health.   Prior to Clarigent, he spent the past decade growing Assurex Health from technology invented at Mayo Clinic and Cincinnati Children’s Hospital Medical Center to a company of over 500 employees serving almost one million people with mental health conditions. Assurex Health was acquired in 2016 by Myriad Genetics then allowing Don to use his more than 25 years of experience to assist others turning their ideas into hyper-growth companies. 

Jeff Levine As CEO, Jeff guides strategy and makes sure his team has everything it needs for success. Jeff has a 30+ year track record of starting and building great companies. Prior companies founded include commercial and consumer electronics manufacturing, from the circuit board to final product, Jeff was responsible for all aspects of business development, marketing, sales, service, and technical support. He graduated from SUNY Stony Brook, BA Economics, and earned his M.I.M. from Thunderbird School of Global Management.

My career has largely been in startup ventures. I have lead and built sales at a start up from zero to $25 million/year, and managed over a hundred million in enterprise product sales in my career. I have also led and built a company from concept to market leadership and “Series B” VC investment. I have contributed to successful exits, via both IPO, and acquisition. I frequently work with other entrepreneurs and executives to help them grow their ideas and organizations.

Kareen is a serial entrepreneur in the field of vascular devices, and was CEO-founder of Setagon, a coronary stent company acquired by Medtronic. She is an LLB, honors graduate from the National University of Singapore, top 2% at the Singapore Bar Examination (PPLC), and was previously an attorney at Drew & Napier in Singapore. She has consulted for government agencies, and spoken on medtech entrepreneurship at Darden (University of Virginia), Singapore-Stanford Biodesign, INSEAD Singapore, National University of Singapore and Singapore Management University.

Dr Brian Thornes is a former orthopaedic surgeon with 17 years of clinical experience, predominantly specialising in trauma. Brian is a serial inventor of several medical devices, most notably the TIGHTROPE®, which is licenced to Arthrex Inc, FL. He is the Founder and Chief Executive of X-BOLT®. Brian has overseen the development the X-BOLT® product portfolio and the validation of the devices in large multi-centre clinical trials.

Brian has a medical degree from Trinity College Dublin, a Masters in Surgery from the National College of Ireland, a Fellowship of the Royal College of Surgeons in Ireland and an MBA from Trinity College, Dublin. Over the past decade, Brian has served on a number of Boards, including Clontarf Orthopaedic Hospital, The King’s Hospital School, and the Higher Education Authority of Ireland.

Brian is a keen golfer at Portmarnock Golf Club, and in the summer enjoys playing cricket at Malahide Cricket Club.

Over 20 years of extensive VLSI and Systems Experience CEO and President-Advancel Logic, COO/Founder Propulsion Networks Senior Management Positions at Synopsys, National Semiconductor.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

A global medical technology and health sciences executive, John Murphy has held leadership roles in large public companies, middle-market private equity businesses, and venture capital environments over the past 20 years. He holds graduate and undergraduate degrees in computer science and a MBA in international finance.

Prior to cofounding VenoStent with Geoff, Tim received his PhD in Biomedical Engineering from Vanderbilt University and is an inventor of the novel shape memory polymers and SelfWrap technologies. While there, he served as an Entrepreneurial Lead in the 2014 NSF I-Corps Program, a pre-intake company in the Life Science Tennessee Mentor Network Program. Before getting his PhD., Dr. Boire worked at Genzyme Corporation as a Research Associate. He received his undergraduate degree from Tufts University in Biochemistry.

Bio coming soon.

Peter Bloch has more than 25 years of experience in leading healthcare and technology companies in the role of Chairman, CEO and previously CFO. This includes experience in both large Pharmaceutical (Sanofi -Aventis) and earlier stage Medical Device and Biotechnology companies (Bionik Laboratories, Tribute Pharmaceuticals and Intellivax).

Dr. Marsteller is a serial medical device entrepreneur and co-innovator of the RadianceTx technology. He previously founded Salutaris Medical Devices, Inc. – invested in by ophthalmic market leader HOYA (7741:Tokyo, Market Cap $21B, $4.5B in annual sales). He is a Medical Doctor (University of Arizona College of Medicine), and physicist (Yale University Graduate School). Dr. Marsteller has Investment Banking experience as an Analyst at Lehman Brothers, and subsequently Morgan Stanley.

Wayne is an experienced healthcare CEO, former corporate finance and venture capital professional and a qualified Doctor of Chiropractic Medicine. He has led several early-stage ventures in commercialising medical technologies including the consolidation and sale of Australian dental practices and a national, corporate-based musculoskeletal therapeutic business. Wayne was previously a Director at Credit-Suisse where he structured and managed M&A and capital market transactions in the media/telco and pharmaceutical sectors. He has previously taught financial restructuring in the Macquarie Applied Finance master's degree and currently teaches investment management at University Technology Sydney. Wayne graduated from Macalester College in St. Paul, Minnesota, The London School of Economics, Harvard Business School and Macquarie University.

Under Matthieu’s leadership, FEops has transformed from a small academic spin-off into a fast-growing venture capital backed gazelle in the medtech sector. He completed his degree in engineering at the University of Ghent in 2002 and gained his PhD in 2008 for his research on cardiovascular device and procedure modeling. 

Aly was born and raised in Cairo, Egypt and got his Bachelor’s degree in Electrical Engineering from Aston University in the UK. After joining the Research In Motion (BlackBerry) team in the London based European Head Quarters as a Systems Integration Engineer, Aly moved back to Egypt to Join the Founding team as COO at KarmSolar, a 4 person Startup that grew into the largest solar energy integrator in the Egyptian Market. In 2015 Aly was accepted into the MBA program at the Stanford Graduate School of Business, during which he was enrolled at the Stanford Biodesign Innovation Program where he developed a passion for Medical Technologies, particularly the Chronic Disease Treatments fundamental shift from In-center brick and mortar facilities to outpatient home-based care. Aly’s passion for deploying cutting edge technology – typically restricted to consumer tech – in the HealthCare space to meaningfully impact lives and provide unprecedented data driven remote patient
management eventually led to the founding of CloudCath in 2017.